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 Alzheimer’s disease (AD) is associated with decreased brain energy 
metabolism.  Hypometabolism in the posterior cingulate cortex (PCC) occurs 
before the onset of memory deficits in subjects at genetic risk for AD who are not 
yet cognitively impaired.  There is a specific inhibition in cytochrome oxidase 
(C.O.) in the PCC, an area involved in spatial navigation.  Creating an animal 
model that exhibits the early pathophysiology of AD is important for developing 
and testing drugs that could reverse memory problems associated with such 
deficits.  Methylene blue (MB) is a compound that improves C.O. activity and 
memory retention in rats. 
 This dissertation had three specific aims:  1) to examine if isolated PCC 
hypometabolism causes spatial memory deficits in rats; 2) to find a dose of MB 
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that improves memory without nonspecific behavioral effects; and 3) to prevent 
memory deficits from PCC hypometabolism with low dose MB. 
PCC hypometabolism was produced by focal administration of sodium 
azide, an inhibitor of C.O. activity.  PCC hypometabolism resulted in impaired 
spatial memory in a hole board food-search task, increased oxidative damage, 
and neurotoxicity in the PCC.  In addition, PCC hypometabolism resulted in 
reduced inter-regional correlations in brain activity. 
Our second set of studies examined the dose-response effects of MB.  
Our findings demonstrated that a low dose of MB: 1) enhanced memory in open 
field habituation and object recognition tasks; 2) did not affect general locomotor 
activity, exploration, motivation, or anxiety; and 3) increased brain oxygen 
consumption 24 hr after in vivo administration.   
Finally, our last study found that low dose MB prevented the deficits 
caused by PCC hypometabolism.  MB did not prevent PCC inhibition or cell loss 
caused by sodium azide.  Inter-regional correlations of brain metabolic activity 
suggested that rats treated with MB were using a different, but equally efficient, 
strategy for memory retrieval. 
This animal model of C.O. hypometabolism in the PCC can provide 
information to understand the mechanisms that regulate early pathological 
degeneration and reveal new therapeutic strategies aimed at reducing or 
preventing cognitive decline.  Studies of low dose MB in humans are needed to 
examine its effects in AD patients. 
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Chapter 1:  Modeling the Early Pathophysiology of Alzheimer’s 
Disease 
Alzheimer’s disease (AD) is associated with decreased brain metabolism.  
Studies of Alzheimer’s patients reveal a specific inhibition in mitochondrial 
cytochrome oxidase (C.O.) in the posterior cingulate cortex (PCC), an area 
involved in spatial navigation.  Hypometabolism in the PCC occurs before the 
onset of memory deficits in (1) subjects at genetic risk for AD who are not yet 
cognitively impaired and (2) subjects with mild cognitive impairment who later 
develop AD. 
There is a need to model the early pathophysiology of AD.  In the United 
States alone, 4 million people are affected with an estimated annual cost of $100 
billion (National Institute on Aging).  It is important to accurately model the 
metabolic deficits in early-stage AD because the disease is irreversible, and most 
therapeutic drugs are effective only in the early to middle stages of AD 
(Silverman, 2004).  Creating an animal model that exhibits the early 
pathophysiology of AD is important for developing and testing drugs that could 
reverse memory problems associated with such deficits.   
1.1.  Alzheimer’s Disease 
Alzheimer’s disease is a progressive neurodegenerative disorder that is 
clinically manifested as dementia that affects memory, mood, and behavior.  A 
diagnosis of probable AD requires fulfillment of the following criteria, which were 
developed by a joint task force of the National Institute of Neurological and 
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Communicative Disorders and Stroke and the Alzheimer’s Disease and Related 
Disorders Association (NINCDS-ADRDA) (McKhann et al., 1984):   
(1)  Dementia established by clinical examination and documented by the 
Mini-Mental Test, Blessed Dementia Scale (or some similar 
examination) and confirmed by neuropsychological tests; 
(2)  Deficits in two or more areas of cognition (for example, word 
comprehension and task-completion ability); 
(3)  A progressive worsening of memory and other cognitive functions; 
(4)  A lack of disturbance of consciousness; 
(5)  An onset between ages 40 and 90, most often after age 65; and 
(6)  An absence of systemic disorders or other brain diseases that could 
account for the progressive deficits in memory and cognition. 
AD is confirmed postmortem by the existence of abnormal protein 
deposits in the brain, namely insoluble amyloid plaques and neurofibrillary 
tangles, but there is considerable debate on the relationship between cognitive 
decline and the underlying neuropathology.  The cause of AD is unknown.  It has 
been proposed that genetic mutations, especially those in mitochondrial DNA, 
intensify other risk factors, including low education, head injury, vascular disease, 
high cholesterol, and age (Blennow et al., 2006).  Age is the most significant risk 
factor among those proposed.   
1.1.1  Impaired Energy Metabolism in Alzheimer’s Disease in vivo 
There is a growing consensus that impaired energy metabolism is a 
critical component in AD.  AD is associated with reduced neuronal metabolism 
which correlates to the degree of dementia and the duration of symptoms (Chase 
et al., 1984).  Studies of cerebral blood flow consistently show a decrease in 
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blood perfusion in AD patients (for review, see Silverman, 2004).  Positron 
emission tomography (PET) imaging that reveals fewer correlations between 
parietal and frontal lobe metabolism in AD patients than healthy controls 
suggests that a breakdown of organized functional activity is also a hallmark of 
AD (Horwitz et al., 1987).  Thus, energy hypometabolism is a consistent feature 
of AD.   
Of all the regions of the brain, the PCC displays the greatest decrease of 
glucose utilization in patients in the early stages of Alzheimer’s disease 
(Minoshima et al., 1997).  This decrease cannot be explained by 
histopathological markers such as plaques and tangles that are found in 
relatively lower amounts in this region (Valla et al., 2001).  Metabolic inhibition in 
the PCC occurs before the onset of memory deficits in (1) subjects who are at 
genetic risk for AD but are not yet cognitively impaired (Reiman et al., 1996) and 
(2) subjects with mild cognitive impairment who later develop AD (Mosconi, 
2005).  In fact, metabolic reductions in the parieto-temporal cortex and the PCC 
are considered to be the most reliable indicators of early AD (Chetelat et al., 
2001; Mosconi, 2005; Borroni et al., 2006).   
1.1.2  Impaired Energy Metabolism in Alzheimer’s Disease in vitro 
The majority of neuronal energy is provided by mitochondrial oxidative 
phosphorylation (OXPHOS; Figure 1), which constitutes the major cellular ATP-
producing mechanism under aerobic conditions.  There are five enzymatic 
protein complexes (complexes I–V) located in the mitochondrial inner membrane 
that catalyze OXPHOS.  Electrons are passed through these enzymes until they 
reach the fourth complex, cytochrome c oxidase (C.O.), the terminal enzyme in 
the mitochondrial electron transport chain.  C.O. catalyzes the final transfer of 
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electrons from cytochrome c to molecular oxygen.  Concomitantly, protons are 
pumped through the enzymes from the matrix into the inner membrane space, 
creating a proton gradient.  This stored energy is used by complex V (ATPase) to 
convert ADP into ATP.  In the brain, ATP is used to perform a variety of tasks 
including transport, neurotransmitter synthesis, and, importantly, repolarizing 
cellular membranes.  
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Figure 1.1 Schematic of the mitochondrial electron transport chain and 





C.O. gene expression is upregulated in response to high energy demand 
(Wong-Riley et al., 1998).  Therefore, neuronal demands regulate C.O. levels 
and distribution.  Furthermore, the Na+/K+ pump that maintains the cellular 
electrical potential is co-localized with C.O. within neurons (Hevner et al., 1992); 
thus, C.O. activity can be used as a marker of neuronal activity.  Levels of C.O. 
are higher in brain cells and areas of the brain that have excitatory input, which 
indicates that C.O. significantly contributes to the energy needed to repolarize 
the membrane potential after neural activity (Wong-Riley et al., 1998).  C.O. is 
composed of 13 subunits and requires bigenomic regulation.  The first three 
subunits (I–III) are encoded by mitochondrial DNA (mtDNA) and are responsible 
for catalytic activity.  The remaining subunits (IV–XIII) are encoded by nuclear 
DNA (nDNA) and perform functions relating to structure, allosteric binding, and 
proton pumping.  Coordinated expression between the subunits from mtDNA and 
nDNA is necessary for the proper function of C.O. 
Approximately 95–98% of brain oxygen is consumed through C.O. and the 
remaining 2–5% forms free radical oxygen species (Floyd, 1999).  A dysfunction 
in any part of OXPHOS increases the generation of free radicals and, 
consequently, increases the oxidation of lipid, protein, and genomic 
macromolecules (Wallace, 1999; Beal, 2005).  Postmortem analysis of AD brain 
tissue reveals that the detrimental effects mentioned above are increased (for 
reviews, see Smith et al., 1995; Markesbery, 1997; Perry et al., 2000).  For 
example, AD brain tissue shows increased mtDNA and nDNA damage as 
compared to control tissue (Mecocci et al., 1994).  Furthermore, the damage to 
mtDNA is greater than damage to nDNA in tissue from AD patients, which 
suggests that mtDNA is more susceptible to oxidative stress (Mecocci et al., 
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1994).  RNA oxidative damage in AD tissue is increased in the hippocampal 
formation, subiculum, and entorhinal cortex, as well as in the frontal, temporal, 
and occipital neocortices (Nunomura et al., 1999).  There is also evidence that 
tissue from AD patients exhibits increased oxidative damage to proteins (Smith et 
al., 1998) and cell membranes (Mecocci et al., 1996).  The damage to DNA, 
proteins, and lipids may contribute to the neurodegenerative process in AD.  
These events can increase membrane permeability, leading to NMDA receptor-
mediated excitotoxicity and cell death.   
 In postmortem brain tissue from AD patients, the respiratory enzymes of 
the electron transport chain are less active than those in control samples; of all 
the enzymes reduced, C.O. is the least active (Mutisya et al., 1994; Parker et al., 
1994b).  Certain areas of the brain are affected more than others.  In comparison 
with control subjects, patients with AD show less C.O. activity in the frontal, 
temporal, and parietal association cortices than in the occipital cortex, putamen, 
or the hippocampus (Kish et al., 1992).  The reduction of C.O. activity cannot be 
explained solely through the loss of brain cells, as there was a significant 
reduction in C.O. activity in the frontal cortex, which is an area not typically 
affected morphologically in AD.  Likewise, there was no significant difference in 
C.O. activity between the control hippocampus and the AD hippocampus (Kish et 
al., 1992), which is an area with a large number of plaques, tangles, and cell loss 
(Thal et al., 2000).   
In AD patients, C.O. activity is observed to be lower not only in brain 
tissue (Kish et al., 1992; Mutisya et al., 1994; Parker et al., 1994b), but also in 
peripheral tissue, such as blood platelets  (Parker et al., 1994a; Valla et al., 
2006b) and fibroblasts (Curti et al., 1997).  Parker Jr. et al. (1994b) did not find a 
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change in the concentration of respiratory electron carriers or redox sites.  In 
addition, they analyzed isolated C.O. protein and were able to detect the low-
substrate binding site in control but not AD tissue (Parker and Parks, 1995).  
Therefore, C.O. inhibition in AD may be a result of abnormal catalytic activity of 
the enzyme rather than from a loss of the enzyme itself that might occur from a 
loss of cells or mitochondria.   
Analysis of C.O. subunit profiles from AD patients suggests that the 
mitochondrial-encoded subunits may be affected more than nuclear-encoded 
subunits.  In brains unaffected by AD, the mRNA levels of mitochondrial-encoded 
subunits I and III in the midtemporal association cortex and the primary motor 
cortex are the same; in brains affected by AD, however, this is not the case 
(Chandrasekaran et al., 1994).  In AD brains, the mRNA levels of mitochondrial-
encoded subunits I and III in the midtemporal association cortex are 50–65% 
lower compared to the primary motor cortex of AD brains and the midtemporal 
assocation cortex from control brains (Chandrasekaran et al., 1994).  Within the 
hippocampus, Simonian and Hyman (1994) also found differences in a 
mitochondrial-encoded subunit (II) between AD and control brains but did not find 
a difference in nuclear-encoded subunit IV.  Chandrasekaran et al. (1997), on the 
other hand, did find decreases in subunit IV in the hippocampus.  Some authors 
suggest that AD is caused by a primary genetic defect in C.O., while others 
suggest that inhibition of C.O. is a secondary effect of decreased neuronal 
activity.  However, decreased neuronal activity does not explain the systemic 
inhibition of C.O. activity observed in platelets and fibroblasts from AD patients.   
A decrease in C.O. activity in brain and peripheral tissue supports the 
hypothesis that a primary defect in C.O. causes AD.  Additional evidence 
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supporting a primary mitochondrial deficit comes from hybrid cells, which are 
cells whose mitochondria have been replaced with mitochondria from AD 
patients.  Hybrid cells show decreased activity in C.O. but not in complex I 
(Sheehan et al., 1997).  The decreased C.O. activity in these cells led to 
increased oxidative stress, reduced ATP, and changes in calcium homeostasis 
and membrane potential (Swerdlow et al., 1997; Cassarino et al., 1998; Ghosh et 
al., 1999; Cardoso et al., 2004b). 
1.2  Posterior Cingulate Cortex 
1.2.1  Metabolic Inhibition in Alzheimer’s Disease 
Postmortem analysis of the PCC of AD patients shows a significant 
decrease in C.O. activity in each of the six layers of the PCC when compared 
with the C.O. activity in control tissue (Valla et al., 2001).  In AD brains, the 
decrease in the superficial PCC layers (I–II) was greater than the decrease in the 
deep layers (III–VI).  In addition, the decrease in C.O. activity in layer I was 
directly associated with the duration of the disease.  The superficial layers 
contain the synaptic neuropil which consumes a great amount of energy due to 
repolarization following action potentials (Valla et al., 2001).  The adjacent motor 
cortex in AD patients showed a similar, but nonsignificant, pattern of C.O. 
inhibition as compared to control subjects.  There were no differences in complex 
II activity between the AD and control groups, confirming a specific defect in C.O. 
in AD patients.   
In healthy human subjects, the PCC shows high levels of baseline activity 
in PET imaging studies (Minoshima et al., 1997).  The PCC contains many 
glutaminergic excitatory synapses that require a substantial amount of energy to 
repolarize the cellular membrane (Hevner et al., 1992).  This high energy 
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demand renders the PCC vulnerable.  For example, a systemic injection of an N-
methyl-D-aspartic acid (NMDA) antagonist in rats produces region-specific 
neurotoxicity, with the PCC being the most affected area (Li et al., 2002).  
Likewise, the PCC may be one of the first areas affected by C.O. inhibition, which 
compromises energy generation and, eventually, cell survival. 
Clinical deficits correspond to hypometabolism in specific regions of the 
brain.  For example, poor performance in language tests is correlated with 
hypometabolism in the left temporal lobe (Chase et al., 1984).  C.O. inhibition in 
the PCC may be related to spatial memory deficits that are common in AD (Hof 
and Morrison, 1990; de la Torre, 2000; Holroyd and Shepherd, 2001). 
1.2.2  General Functions of the PCC 
The PCC is a division of the medial limbic cortex and lies dorsal to the 
caudal aspect of the corpus callosum.  Anatomical-connectivity studies show that 
the PCC is connected with motor, visual, and subicular cortices, as well as the 
anterior thalamus (Vogt and Miller, 1983; Sanderson et al., 1991; van Groen and 
Wyss, 1992a; Shibata, 1994, 1998, 2000; van Groen and Wyss, 2003; Shibata et 
al., 2004).  The PCC is included in the Papez circuit.  The pathway includes the 
following areas as seen in Figure 2 (Papez, 1937; Vertes et al., 2001).  
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The PCC is in a strategic position to mediate signals between the 
hippocampal formation, thalamus, and cortex.  Papez (1937) originally proposed 
that the functional anatomy of this circuit may underlie emotion, but its function 
has recently been reformulated to include processes of learning and memory 
(Harker and Whishaw, 2002; van Groen et al., 2004).  The two propositions are 
not mutually exclusive.  In fact, emotional states facilitate learning and memory 
(for review, see Packard and Cahill, 2001).   
The PCC contributes to several processes.  The human PCC participates 
in tasks of emotional processing (Aleman, 2005; Malhi et al., 2007), which may 
explain its involvement in bipolar disorder (Nugent et al., 2006; Roth et al., 2006) 
and schizophrenia (Franck et al., 2002; Haznedar et al., 2004; Shimizu et al., 
2007).  Functional imaging of healthy individuals reveal that the PCC is engaged 
while both encoding and retrieving episodic memories (Nyberg et al., 1996; 
Desgranges et al., 1998; Krause et al., 2006).  The PCC is activated during route 
recall and landmark memory tasks (Maguire, 1997; Ohnishi et al., 2006).  In rats, 
the PCC is involved in functions that include fear-based learning (Mello e Souza 
et al., 1999; Souza et al., 2002) and conditioned discrimination (Gabriel, 1993; 
Bussey et al., 1996).  It also plays a significant role in spatial navigation and 
memory.   
1.2.3  Studies Supporting a Role of the PCC in Spatial Memory  
The PCC receives information from thalamic nuclei and the subiculum to 
allow for learning of specific sensory stimuli and changing a behavioral response 
according to previous experiences (Gabriel, 1993).  Reciprocal connections with 
the entorhinal cortex suggest that the PCC analyzes objects spatially and sends 
this information to the hippocampal formation for further processing (Warburton 
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et al., 1998).  Substantiating this theory, one study revealed a significant increase 
in gene expression in the PCC in rats performing a radial arm maze task (Vann 
et al., 2000).   
1.2.3.1  Animal Studies 
Head-direction cells are located in several areas of the Papez circuit 
including anterior thalamic nuclei, the subiculum, and the PCC (Chen et al., 
1994; Taube, 1998).  These cells respond when the animal faces a specific 
direction, regardless of the animal’s location in the environment.  Interestingly, 
head-direction cells are also found in the striatum (Taube, 1998), which is not 
included in the Papez circuit, but is connected to the PCC (McGeorge and Faull, 
1989; van Groen and Wyss, 1992b; van Groen and Wyss, 2003).  Cho and 
Sharp (2001) elaborated on the firing characteristics of PCC cells with spatial 
correlates:  they not only verified the existence of head-direction cells in the PCC, 
but they also identified cells that fired to certain combinations of place, head 
direction, and running speed.  Their findings, along with the fact that the PCC is 
connected to the motor cortex, confirm that the PCC has a role in path integration 
and/or landmark navigation.   
Complete removal of the PCC generally produces spatial impairment in 
rats.  The removal of the PCC impairs learning and memory in both the single-
place and the place-alternation versions of the Morris water maze, which is a 
behavioral test commonly used to assess spatial memory (Sutherland et al., 
1988).  In the typical procedure for the single-place navigation (reference 
memory) test, a rat is placed randomly in different start positions in a pool of 
water containing a hidden escape platform in a fixed location.  The rat learns to 
find the platform by using the visual cues placed around the pool.  After a few 
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trials, rats become very proficient in finding the hidden platform.  A probe test is 
often performed the day after the acquisition phase.  In the probe test, the rat is 
placed in the same pool of water but the platform is removed; the percentage of 
time it spends in each pool quadrant is analyzed.  Nonimpaired rats spend more 
time swimming in the quadrant where the platform was located during 
acquisition.  The place-alternation (working-memory) version of this task differs in 
that the platform location changes daily.  Whishaw et al. (2001) removed the 
PCC in Long-Evans rats and tested allocentric and egocentric navigation using 
the Morris water maze, a food-search task, and matching-to-place tasks.  They 
observed impairment in all navigation tasks.   
Vann & Aggleton (2002) administered an excitotoxic lesion from the level 
of the fornix to almost the caudal limit of the cerebral cortex and examined the 
effects in several tests of allocentric and egocentric learning.  Agouti rats were 
impaired in two tasks of allocentric learning:  the radial arm maze and the water 
maze.  However, there were no group differences in T-maze alternation, a task of 
egocentric discrimination.  Interestingly, there was a group difference in an 
object-in-place spatial task.  In this task, rats explored four different objects that 
are placed in the chamber.  After a delay of 15 minutes, two objects were 
switched in location.  When the rats were reintroduced to the chamber, the PCC-
lesioned rats did not explore the newly-located objects as long as control rats.  
But results from other studies in which the PCC was inflicted with 
excitotoxic lesions rather than complete removal are less consistent.  Riekkinen 
et al. (1995) tested three groups of Wistar rats in the water maze.  One group 
was injected with an anticholinergic drug in the PCC before training, one group 
was injected after training, and the last group was injected before testing.  Only 
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the rats injected before training were impaired.  However, when Agouti rats were 
injected with an excitotoxin in the  PCC before training in the water maze, no 
impairments were observed in single-place or place-alternation training, or in 
probe trials (Warburton et al., 1998).  The results from the Warburton study 
(1998) agree with an earlier study that did not find impairment in Agouti rats in 
three tests of spatial memory when the PCC was lesioned with an excitotoxin 
(delayed nonmatching-to-position and spatial reversal learning in a spatial 
discrimination task, and forced alternation in a T-maze) (Neave et al., 1994).  
Conversely, a later study examining PCC-lesioned Sprague-Dawley rats found 
significant impairment in the place-alternation version of the water maze (van 
Groen et al., 2004). 
These inconsistent results from PCC lesion studies led Harker & Whishaw 
to test two strains of rats (2002).  They used Long-Evans, which showed 
impairments from PCC lesions, and Agouti rats, which did not.  This study 
revealed that control Long-Evans rats performed better than control Agouti rats in 
the water maze.  Removal of the PCC in Long-Evans rats impaired their behavior 
in the single-place and the place-alternation water maze tasks compared to 
control Long-Evans rats.  Control Agouti and PCC-lesioned Agouti rats were not 
different from each other in the single-place task, but both performed worse than 
control Long-Evans rats.  Furthermore, PCC-lesioned Agouti rats performed 
poorly on the more demanding place-alternation task relative to control Agouti 
rats.  The performance of the strains in a visual acuity test was not different.  
Thus, the PCC was shown to be important in spatial behavior in both strains, but 
an innate nonspatial deficit in the Agouti rat may disguise the role of the PCC in 
the water maze task.   
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Single-cell recordings of neurons in the PCC during discrimination learning 
suggest that cingulate neurons may be important in long-term retention of 
memory.  In a discriminative avoidance procedure, an animal learns to respond 
to a tone that predicts a foot shock (positive conditioned stimulus) and they learn 
to ignore a different tone that is not followed by foot shock (negative conditioned 
stimulus).   In the PCC, discriminative neuronal activity occurs during the positive 
conditioned stimulus relatively late in learning (Gabriel, 1993).  Consistent with 
this, rats with neurotoxic PCC lesions are impaired during the late, but not early, 
stages of acquisition in a conditioned visual discrimination task (Bussey et al., 
1996).   
While there is disagreement as to the exact contribution of the PCC to 
spatial learning, it is evident that the PCC is involved in spatial processes.  
Lesion studies, along with PCC connections to visual, motor and subicular 
cortices, suggest that the PCC has a role in navigation, perhaps with a bigger 
contribution during the late stages of learning.  Although there is debate as to 
whether the PCC is involved more in navigation using allocentric cues (ones that 
are both external and independent of the animal’s body position) or navigation 
using egocentric cues (those generated from self-movement), the fact that there 
is a spatial function within the PCC is undeniable.  The human literature confirms 
and extends these findings.   
1.2.3.2  Human Studies 
One interesting case study described a patient with topographical 
amnesia, a condition that refers to the inability to navigate because of the failure 
to use landmarks for route finding (Cammalleri et al., 1996).  The patient was 
unable to find his way in familiar or unfamiliar environments.  MRI revealed a 
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tumor between the anterior and posterior cingulate cortices.  Another study 
discussed a patient with a lesion in the PCC and who also had topographical 
disorientation.  This patient also got lost in new environments, but unlike the 
aforementioned patient, she was able to navigate in familiar surroundings 
(Katayama et al., 1999). 
In healthy human subjects, PCC activation is strongly correlated with the 
speed of target detection during a spatial attention task (Mesulam et al., 2001).  
The PCC also responds when subjects are visualizing a previously learned route, 
including the landmarks and their movements along this route (Berthoz, 1997).  
This work is consistent with the animal research that showed the presence of 
head-direction cells (Cho and Sharp, 2001).  Furthermore, the PCC was also 
involved in tasks in which subjects remembered environments recently learned 
and environments very familiar (Maguire, 1997).  Taken together, both animal 
and human studies support the hypothesis that the posterior cingulate is involved 
in spatial memory.   
1.3  Sodium Azide:  An Inhibitor of Cytochrome Oxidase as Model of AD 
Sodium azide is a toxin that specifically inhibits C.O. activity, and therefore 
oxygen metabolism, which results in a form of chemical hypoxia.  Based on the 
findings of reduced C.O. activity in blood platelets from AD patients, Bennett et 
al. (1992) developed a rat model of chronic C.O. inhibition by implanting 
subcutaneous pumps that delivered a constant rate of sodium azide.  Rats 
receiving 24 mg/kg/day showed a significant decrease (35%) in C.O. activity and 
a decrease in long-term potentiation, which is a proposed cellular correlate of 
memory formation.  This treatment also decreases protein kinase C, a regulator 
of many cellular processes (Bennett et al., 1995).  Behaviorally, rats were 
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impaired in spatial learning in a radial arm maze and Pavlovian conditioning in a 
shuttle box task (Bennett et al., 1992).  Another study found impairments in 
sodium azide-treated rats in the Morris water maze (Bennett and Rose, 1992).  
These impairments were not due to sensorimotor deficits, as measured by open 
field activity and flinch-jump testing (Bennett et al., 1992).  The spatial memory 
deficits produced by the chronic subcutaneous infusion of sodium azide were 
later verified in our laboratory using a baited holeboard task (Callaway et al., 
2002). 
Regional C.O. activity in the brain was measured after chronic sodium 
azide administration (Cada et al., 1995).  After two weeks of subcutaneous 
treatment, all 22 regions sampled showed a significant reduction in C.O. activity 
when compared with that of saline-treated animals.  The enzymatic reduction 
ranged from 26% to 37%.  There were also different correlations of C.O. activity 
between brain regions in control versus azide-treated brains.  Therefore, 
systemic inhibition of C.O. activity can cause regional vulnerability, perhaps due 
to regional differences in energy demand or C.O. gene expression 
(Chandrasekaran et al., 1992).  Luques et al. (2007) recently demonstrated that 
systemic treatment resulted in signficant C.O. inhibition in the PCC after four 
weeks of administration.   
Another study used sodium azide to locally impair metabolism in the rat 
striatum (Brouillet et al., 1994).  Intrastriatal administration of 1.5 M, 2 M, and 3 M 
sodium azide reduced levels of several neurochemicals, including dopamine, 
GABA, substance P, somatostatin, and neuropeptide Y.  These decreases were 
age and dose dependent.  At the highest dose, there were decreases in ATP and 
increases in lactate, neuronal loss, and gliosis.  However, Brouillet et al. (1994) 
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did not measure behavior changes associated with focal administration of sodium 
azide. 
In vitro, inhibition of C.O. activity by 3 mM sodium azide increases the 
accumulation of insoluble amyloid fragments (Gabuzda et al., 1994), while 500 
µM–1 mM sodium azide decreases the amount of soluble fragments but does not 
result in a loss in cell viability (Gasparini et al., 1997).  Accumulation of insoluble 
amyloid deposits is one of the pathological features in the brains of AD patients.  
Sodium azide induces heat shock protein activity and increases lipid peroxidation 
in vitro, which is similar to hypoxic conditions (Kositprapa et al., 2000).  Sodium 
azide-inhibited cells increased the production of superoxide and hydrogen 
peroxide, which may lead to oxidative damage (Partridge et al., 1994).  An 
increase in hydroxyl radical production was found in vivo in sodium azide-treated 
rats (Smith and Bennett, 1997).  Furthermore, sodium azide treatment in vivo 
changes the cellular distribution of kynurenine aminotransferase, an endogenous 
NMDA antagonist (Knyihar-Csillik et al., 1999).  Thus, sodium azide 
administration in rats may be useful for modeling the impaired physiological and 
behavioral features of AD. 
Studies in this and other laboratories have shown that chronic sodium 
azide administration produces memory retention deficits in rats (Bennett et al., 
1992; Bennett and Rose, 1992; Callaway et al., 2002).  We propose that C.O. 
inhibition in the PCC will result in deficits in a spatial holeboard task in rats.  If a 
positive correlation is found between the inhibition of mitochondrial metabolism in 
the PCC and spatial memory impairment, then the development of this animal 
model can provide a tool for studying the pathophysiology of AD and assessing 
drugs for treating AD.   
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1.4  Methylene blue:  A Therapeutic Candidate for Alzheimer’s Disease 
Methylene blue (MB) is a phenothiazine drug approved by the U.S. Food 
and Drug Administration for the treatment of methemoglobinemia (Wright et al., 
1999).  It is colored in its oxidized state and colorless after a two-electron 
reduction.  It was first used as a biological dye by Paul Ehrlich to differentiate live 
cells from dead cells.  In 1886, Ehrlich injected MB into living rats and described 
it as a selective vital stain for nerve cells and their processes (Foot, 1954).  Since 
then, MB has been widely used in biology and chemistry as a redox indicator and 
dye.  MB has been safely used for a number of pharmacological applications 
such as treating manic-depressive psychosis (Narsapur and Naylor, 1983; Naylor 
et al., 1986) and severe depression (Naylor et al., 1987).  MB has also been 
used for the preventive treatment of drug-induced encephalopathy (Kupfer et al., 
1996; Wainwright and Crossley, 2002). 
1.4.1  Biochemical Effects of Methylene Blue 
MB is a lipid-soluble compound that has a low molecular weight and can 
penetrate cellular membranes. MB has cationic and lipophilic properties that 
attract it to the mitochondrial membrane (Visarius et al., 1999).  After in vivo 
administration, MB passes through the blood-brain barrier and accumulates in 
the human brain within hours (Peter et al., 2000).  Thiazine reductase reduces 
MB to leucomethylene blue (LMB) on the cell surface (Merker et al., 1997).  After 
LMB diffuses inside, it is reoxidized and sequestered inside organelles such as 
mitochondria and/or lysosomes (Merker et al., 1997; Gabrielli et al., 2004).   
Although microscopy has not revealed a specific site (Buehring and 
Jensen, 1983), numerous studies support the theory that MB acts within 
mitochondria.  Scott et al. (1966) systematically used different mitochondrial 
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inhibitors and concluded that MB accepts electrons near complex I and complex 
III, forming LMB.  Afterwards, LMB donates electrons near cytochrome c, which 
is the electron carrier between complexes III and IV.  Within mitochondria, low 
concentrations of MB stimulate cellular respiration in the rat liver (Visarius et al., 
1997) and rat brain (Riha et al., 2005), and increase cytochrome c oxidation in 
the rat brain (Callaway et al., 2004).   
One hypothesis that explains the myriad of uses for this compound is that 
MB has an affinity for proteins containing iron (May et al., 2003).  MB is 
commonly used to treat drug-induced methemoglobinemia.  This condition is 
characterized by the accumulation of methemoglobin, a form of hemoglobin that 
cannot bind oxygen.  MB accepts electrons from NADPH-dependent 
methemoglobin reductase and donates the electrons to methemoglobin, thereby 
converting it back into oxygen-carrying hemoglobin.  MB also prevents and 
reverses neurotoxicity caused by ifosfamide chemotherapy by inhibiting 
monoamine oxidase, which prevents the excitatory effects of ifosfamide (Kupfer 
et al., 1996; Lerch et al., 2006).  Moreover, MB restores oxygen consumption in 
fish gills treated with rotenone, a complex I inhibitor, by transferring electrons 
downstream of complex I and allowing OXPHOS to continue (Lindahl and Oberg, 
1961).  Additional targets of MB include endothelial nitric oxide synthase, 
cytochrome c-dependent reductase (May et al., 2003), and glutathione (Kelner 
and Alexander, 1985). 
In a model of ischemia-reperfusion using tissue slices, it was shown that 
MB treatment prevents the formation of free radicals such as superoxide (Salaris 
et al., 1991).  During ischemia, there is a buildup of oxygen that is reduced to 
superoxide by xanthine oxidase upon reperfusion.  MB prevents the reduction of 
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oxygen to superoxide by accepting two electrons at the iron-sulfur center of 
xanthine oxidase.  LMB then transfers two electrons to oxygen, producing 
hydrogen peroxide rather than the more dangerous superoxide radical.  MB also 
inhibits nitric oxide synthesis (Mayer et al., 1993) and prevents lipid peroxidation 
caused by complex I inhibition (Zhang et al., 2006).  The antioxidant properties of 
MB would be beneficial to patients with AD, as an increase in free radical 
production and a decrease in antioxidants is associated with neurodegenerative 
diseases (Smith et al., 1995; Markesbery, 1997; Perry et al., 2000). 
1.4.2  Memory-enhancing Effects of Methylene Blue 
Martinez et al. wrote the first report of the ability of MB to improve memory 
(1978).  They found that a low dose of MB (1 mg/kg) injected in rats post-training 
enhanced the memory of an inhibitory avoidance response when tested 24 h 
later.  This effect did not occur when MB was injected 15 minutes before training, 
6 hours after training, or 15 minutes before testing.  Therefore, low dose MB 
does not facilitate memory by affecting retrieval or performance but rather 
through enhancing memory consolidation immediately after training.  Conversely, 
a high dose of MB (50 mg/kg) administered to mice 15 minutes before training 
produced a retention deficit (Martinez et al., 1978).   
Recent studies in our laboratory examined the effects of 1 mg/kg and 4 
mg/kg doses in appetitive and aversive tasks.  These studies provide evidence 
that MB improves memory retention without modifying anxiety (Callaway et al., 
2002; Callaway et al., 2004; Gonzalez-Lima and Bruchey, 2004; Wrubel et al., 
2007).  When rats treated chronically with sodium azide are administered 1 
mg/kg MB post-training, their reference memory in a baited holeboard task is 
restored to the level of control rats (Callaway et al., 2002).  In this task, 1 mg/kg 
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MB given post-training to normal rats also enhanced memory retention when 
compared with saline-treated animals (Callaway et al., 2004).    
Although low doses of MB improve memory in various tasks, MB has not 
been examined with regard to its effects on locomotor activity and feeding 
behavior, which may contribute to the modification of the behavior observed in 
previous avoidance and appetitive tasks.  For example, MB could simply 
decrease locomotor activity, thereby increasing inhibitory avoidance responses.   
In summary, low-dose MB administered post-training improves memory 
retention when tested 24 hours later in avoidance and appetitive tasks (Callaway 
et al., 2004; Gonzalez-Lima and Bruchey, 2004; Wrubel et al., 2007) and 
restores spatial memory impaired by sodium azide (Callaway et al., 2002).  MB 
may improve memory retention by acting as an antioxidant and metabolic 
enhancer. 
1.5  Specific Aims 
This dissertation will address two general hypotheses.  The first is that 
inhibition of C.O. activity in the PCC is sufficient to cause memory impairment in 
a spatial task.  The second is that low-dose MB treatment can prevent these 
deficits.  The following chapters will explore these topics.  Specifically, the first 
study will test the hypothesis that isolated inhibition of C.O. activity in the PCC 
produces spatial memory deficits in a holeboard food-search task.  Spatial 
memory deficits will be produced in rats by local administration of sodium azide.  
Study 2 will determine what dose of MB improves behavioral habituation and 
recognition memory without nonspecific effects on behavior.  Different doses of 
MB will be evaluated in wheel running, feeding, open field habituation, and object 
recognition tests.  In addition, we will examine the time and dose dependent 
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effects of MB on brain oxygen consumption.  Oxygen consumption is an 
important indicator of neuronal activity (Wong-Riley et al., 1998; Kasischke et al., 
2004).  The measurement of brain oxygen consumption may provide insight into 
cellular mechanisms mediating the effects of MB on memory.  After determining 
an effective MB dose, we will use it in rats treated with sodium azide in the PCC 
to prevent spatial memory impairment (study 3).  Previous studies demonstrate 
that memory difficulties in AD are correlated with impaired mitochondrial 
oxidative metabolism and decreased brain oxygen utilization (de la Torre, 2004; 
Beal, 2005).  MB increases brain mitochondrial metabolism and improves 
memory in rats.  MB may be beneficial for humans with disorders characterized 
by metabolic energy deficiency, such as AD. 
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Chapter 2:  Posterior Cingulate Cortex Hypometabolism Impairs 
Food-rewarded Spatial Memory 
 
2.1  ABSTRACT 
Evidence from human and animal studies supports a role of the posterior 
cingulate cortex (PCC) in spatial orientation and memory.  Human functional 
brain imaging shows that this area is the earliest affected metabolically in 
patients with Alzheimer’s disease (AD) and in patients with mild cognitive 
impairment who later develop AD.  In particular, cytochrome oxidase (C.O.) 
activity is reduced within the PCC in AD.  Inhibition of brain C.O. and resulting 
learning and memory impairments were experimentally induced in rats by 
injecting sodium azide directly into the PCC.  Rats were trained in a baited 
holeboard task, received either sodium azide injections into the PCC or sham 
surgery, and then tested in an unbaited probe trial.  Brains were extracted and 
analyzed for C.O. activity.  In addition, the effect of C.O. inhibition on lipid 
peroxidation, a measure of oxidative stress, was studied in vitro.  Rat brain 
homogenates were exposed to different concentrations of sodium azide and 
quantified using the thiobarbituric acid reactive substances assay.  Although the 
groups did not differ in reference memory in the probe test, a significant within-
subject difference was found.  Only sodium azide-treated rats were impaired in 
their memory of the baited pattern in the probe trial as compared to their training 
scores before treatment.  This was not due to a difference in general activity 
since the time to complete the task and the total number of nosepokes were not 
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different in sodium azide-treated rats than in control rats.  C.O. histochemistry 
revealed a significant decrease in PCC activity in sodium azide-treated rats as 
compared to control animals.  Other brain regions with purported anatomical 
connections to the PCC did not show group differences in average C.O. activity.  
However, interregional covariance analysis of C.O. activity revealed significant 
correlations between the PCC and several other brain regions in the control 
group that were absent in the sodium azide-treated group.  Compared to control 
samples, a seven-fold increase in lipid peroxidation was produced by the 
concentration of sodium azide used in the in vivo experiment.  Thus, C.O. 
inhibition in the PCC resulted in reduced interregional correlations in brain 
activity, an increase in oxidative stress, and memory impairment in a spatial 
holeboard task.  An animal model presenting a metabolic inhibition similar to that 
in early stage AD will advance understanding of the disease by providing 
opportunities to characterize behavior impairments and test therapeutics that 
reverse impairments.
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2.2  INTRODUCTION 
The posterior cingulate cortex is the posterior division of the medial limbic 
cortex.  It is located above the caudal aspect of the corpus callosum.  The 
posterior cingulate includes Zilles’ retrosplenial agranular (RSA) and retrosplenial 
granular (RSG) cortices, rostral to the splenium of the corpus callosum (Bussey 
et al., 1997; Paxinos and Watson, 1997).  Because we did not investigate the 
area caudal to the splenium of the corpus callosum, the term “posterior cingulate” 
cortex (PCC) will be used to describe this cortical region rather than the name 
“retrosplenial” cortex.  Dorsal PCC and ventral PCC will be used to refer to RSA 
and RSG, respectively.  Anatomical connectivity studies show that the PCC is 
connected with motor, visual, and subicular cortices, and the anterior thalamus 
(Berthoz, 1997; Ohnishi et al., 2006).   
The human PCC has a crucial role in spatial memory.  Cammalleri et al. 
(1996) described a patient with a tumor in the PCC who was unable to navigate 
in familiar or unfamiliar surroundings due to the inability to use landmarks for 
route finding.  Functional studies in healthy subjects also provide evidence for a 
role of the PCC in the processing of visually-guided behavior relating to aspects 
of attention, landmarks, and navigation.  A spatial attention task showed fMRI 
activation in the PCC that was strongly correlated with the speed of target 
detection when spatial cues were present (Mesulam et al., 2001).  The PCC was 
also active when subjects were asked to remember visual landmarks and their 
movements along a previously learned route (Berthoz, 1997).  Similarly, Maguire 
et al. (1997) found that the PCC was involved during tasks that required learning 
a room that contained salient objects and empty rooms only distinguished by 
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their shape, as well as remembering environments recently learned and those 
very familiar.    
Animal studies confirm a role of the PCC in spatial navigation and 
memory.  Specific sensory stimuli can activate cingulate neurons, as examined 
with single-cell recordings.  For example, the PCC contains head-direction cells 
that are sensitive to the direction the animal is facing (Chen et al., 1994).  
Furthermore, the PCC may specifically be involved during the late stages of 
learning.  In an active avoidance task, discriminative neuronal activity (cells firing 
to a stimulus that predicts shock) occurs late in learning in the PCC (Gabriel, 
1993).  This is supported by studies showing that lesioning this area before 
acquisition impaired rats only during the late stages of task acquisition (Bussey et 
al., 1996, 1997). 
Lesioning the PCC with N-methyl-D-aspartic acid (NMDA) impaired rats’ 
performance in the radial arm maze, water maze, and an object-in-place task, 
whereby objects are switched in location in the second trial (Vann and Aggleton, 
2002).  Aspiration of the PCC produced deficits in the water maze and matching-
to-place tasks (Sutherland et al., 1988; Whishaw et al., 2001; Harker and 
Whishaw, 2002). 
The evidence from human and animal studies indicates that the PCC is 
involved in spatial navigation, perhaps with a bigger contribution during late 
stages of learning.  This study tested this hypothesis by locally inhibiting PCC 
function after rats were trained in a spatial food-search task, and examining the 
effects on memory retention.  Importantly, rather than using a neurotransmitter-
specific lesion, PCC hypometabolism was produced by administration of sodium 
azide, a mitochondrial toxin that inhibits cytochrome oxidase (C.O.) activity by 
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blocking the transfer of electrons to oxygen.  Cada et al. (1995) previously 
demonstrated that chronic and systemic sodium azide infusion in rats produces 
regional brain differences in C.O. inhibition.  Comparing systemic sodium azide-
treated rats to control rats revealed significant decreases in C.O. activity in all the 
brain regions sampled, including the PCC (Cada et al., 1995; Luques et al., 
2007).  This suggests that the PCC is part of a group of brain regions with distinct 
neurobiological features that renders them more vulnerable to metabolic insults. 
We addressed the hypothesis that isolated PCC hypometabolism is 
sufficient to produce impairment in a spatial memory task.  C.O. histochemistry-
based metabolic mapping was used to analyze brain interregional effects due to 
PCC inhibition.  The local neurotoxic effects of sodium azide administration in 
vivo was further confirmed by determining neuronal and glial densities in the 
PCC.  Finally, we tested the hypothesis that the neurotoxicological effect of C.O. 
inhibition from sodium azide is mediated by an increase in oxidative stress by 
measuring lipid peroxidation in brain tissue after administration of sodium azide 
in vitro.   
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2.3  METHODS 
2.3.1  Pilot Study 
It was previously determined that a 3 M intrastriatal injection of sodium 
azide significantly increased lactate and decreased ATP concentrations after 3 
hours (Brouillet et al., 1994).  However, behavioral effects from this concentration 
were not assessed.  Therefore, a pilot study was conducted to determine if 
behavioral impairment occurs 24 hours after sodium azide administration directly 
into the brain. 
We injected rats in the sensorimotor cortex (SMC) and assessed their 
behavioral function during locomotion.  This area was chosen based on the 
literature showing that lesioning the SMC decreases the use of the impaired 
forelimb in the Schallert cylinder and footfault tests (Schallert et al., 2000; Adkins 
et al., 2004).  Two Sprague Dawley rats each received four injections of 0.5 µL 
sodium azide (3 M sodium azide dissolved in phosphate buffer, pH = 7.4) in the 
SMC using Paxinos coordinates (from Bregma, in mm):  A/P -0.5 to +1.5; M/L 
±3.0 to 4.5; D/V -1.2.  (The details of the surgical procedures are described in a 
later section.)  Measures of forelimb asymmetry were assessed before and 24 
hours following the sodium azide injections, and scored using a slow-play 
videotape.   
The footfault test measured coordinated forelimb placement during 
locomotion.  Rats were placed on an elevated platform (47 cm X 30 cm) 
consisting of grid openings (3.25 cm2 and 2.75 cm2) and allowed to walk on the 
platform for 2 min.  A footfault was defined as a slip of the forelimb through the 
grid openings.  The number of contralateral (impaired) and ipsilateral 
(nonimpaired) forelimb footfaults were counted.  Functional impairment was 
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expressed as the percentage of contralateral footfaults to total footfaults.  Rats 
performed at 48% on the day before surgery and 67% one day following sodium 
azide administration in the SMC.   
The Schallert cylinder test was conducted in a transparent Plexiglass 
cylinder (20 cm diameter X 30 cm height).  Rats were placed in the cylinder 
before and 24 hours after injection and their behavior was videotaped for 2 min.  
We recorded the number of instances that the rat placed one limb on the cylinder 
wall while the animal was rearing and presented the data as a percentage of 
contralateral forelimb use.  In addition, sequential paw placement was also 
assessed.  This parameter was defined as the number of sequential placements 
of the same forelimb on the cylinder wall as the rat is rearing.  Sequential paw 
placements were also presented as a percentage of contralateral use.  In both 
measures, there was a decrease in the use of the impaired (contralateral) limb.  
Pre and post percentages in the asymmetry single use of the contralateral limb 
were 49% versus 33%, and 38% versus 23% in sequential paw placements of 
the impaired limb.  Therefore, in all three measures of forelimb use, 3 M sodium 
azide administration directly into the SMC resulted in functional impairment one 
day following surgery.  Therefore, we tested subjects one day following sodium 
azide injection in the PCC. 
2.3.2  Subjects 
Subjects were 25 male Sprague Dawley rats (Harlan, Houston, TX) 
weighing 225–250 grams upon arrival and single-housed on a 12 h light-dark 
cycle.  After 1–2 days of acclimation, they were placed on a food restriction 
procedure and weighed daily to ensure that their weight did not drop below 85% 
of free-feeding rats of a similar age.  They were fed at the end of each day.  
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Water was freely available.  Rats were handled daily for 5 min on each of the 4–5 
days before habituation began.  On the two days preceding habituation, rats 
were given two sucrose pellets (45 mg, Noyes, Lancaster, NH) in their home 
cage.  All animal procedures were approved by the Institutional Animal Care and 
Use Committee (IACUC) at the University of Texas at Austin, and conform to all 
NIH and USDA guidelines.  All experiments were conducted in facilities approved 
by the Association for Assessment and Accreditation of Laboratory Animal Care 
(AAALAC) International. 
2.3.3  Behavioral Procedures 
2.3.3.1  Apparatus 
The holeboard was a Med Associates open field chamber 43.2 cm2 (St. 
Albans, VT) surrounded by clear plexiglass walls 30.5 cm high.  Inside the 
chamber was a holeboard floor insert with sixteen equidistant-spaced holes (3.2 
cm2) in a 4 X 4 array and an underlying food tray.  The holes were 4.5 cm apart 
and the outer holes were 8.6 cm from the chamber wall.  The bottom insert 
consisted of a bottom tray, a screen and a top tray that were positioned 
underneath the holeboard floor.  The bottom insert contained 16 holes with the 
same dimensions as the holeboard floor.  The wire screen was positioned over 
the holes of the bottom tray which each contained five inaccessible sucrose 
pellets to mask potential odor cues emanating from the food in the baited holes.  
Thus, the rats could not use olfactory cues to discriminate between baited and 
unbaited holes.  The task floor was placed 2 cm over the food tray.  Infrared 
photobeams located just under the surface of the top floor detected entries into 
the holes.  The testing room was dimly lit (33 lux) and contained large spatial 
cues.  The chambers were wiped with a diluted solution of Bio-Clean (Stanbio 
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Laboratories, Boerne, TX) and the task floors were rotated between subjects to 
discourage the use of the previous animal’s markings as a navigational strategy. 
Med Associates computer software recorded the latency to complete each 
trial, novel hole entries, repeat entries and total entries, and organized the data 
by task and non-task.  Reference memory was the index of spatial memory.  
Reference memory was defined as the ratio of the number of visits and revisits to 
the baited holes divided by the total number of visits to baited and nonbaited 
holes. 
2.3.3.2  Habituation & Training 
Rats were run in cohorts of 4–5 rats, resulting in a total number of five 
cohorts.  During habituation, the animals were placed in the holeboard apparatus 
with all sixteen holes baited with one sucrose pellet.  A habituation trial began 
with the first nosepoke and ended after all pellets were consumed or after 5 min 
elapsed.  Trials continued until each rat consumed at least 15 pellets within a 
trial; this criteria was achieved in an average of four trials. 
After 1–2 days of habituation, training began (Table 1).  Four holes were 
baited in a consistent pattern throughout the training procedure (Figure 1).  A trial 
began with the first nosepoke and ended after 5 min or after all 4 pellets were 
consumed.  Each rat received 5 trials per day for a total of 8 days.  Subjects 
remained in the behavioral room until all the rats in their cohort completed 5 
trials.  The average intertrial interval was 10 min.   
Subjects were divided into two groups matched on their pretreatment 
acquisition performance which was calculated by averaging their reference 
memory scores for the 8-day training period.  On the 9th day, surgery was 
performed.  On the day following surgery, they received one unbaited probe trial 
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to test for memory retention.  Thereafter, rats were tested daily for 4 days to 
determine how long the behavioral effects of C.O. inhibition lasted.  Retraining 
was identical to training with the exception of the rats receiving 4 trials per day 
instead of 5 trials. 
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Table 2.1 Experimental design 
 
Sample Size Group Day Procedure Configuration
n = 12 control 1-2 habituation all holes baited
n = 13 sodium azide 3-10 training 4 holes baited
11 surgery
12 probe no baited holes
13-16 retraining 4 holes baited





Figure 2.1 Schematic drawing of the holeboard chamber.  Solid circles 




2.3.4  Surgery 
Subjects were anesthetized using a vaporizing machine (E-Z Anesthesia, 
Euthanex Corp, Palmer, PA).  Animals were induced in a host cage filled with 
97% breathing air and 3% isoflurane (Aerrane, Baxter Pharmaceutical Products, 
Deerfield, IL).  After the rat was fully anesthetized (~ 3 min), they were placed on 
a surgical bed maintained at 37°C with their nose in a cone connected to the 
anesthesia machine.  During the surgical procedure, animals were monitored for 
breathing and anesthesia state, and the concentration of isoflurane was adjusted 
accordingly.   
Rats were placed in the flat skull position in a Stoelting stereotaxic frame.  
The head was shaved, disinfected with Nolvasan (Wyeth, Madison, NJ), and 
Lacrilube (Allergan, Irvine, CA) was applied over the eyes to prevent drying.  A 2 
cm mid-sagittal incision was made over the scalp and a retractor was inserted 
into the skin to expose the area.  The periosteum was removed by scraping with 
cotton swabs.  Bone wax (Ethicon, Somerville, NJ) was used to stop bleeding, if 
necessary.   
After drilling 0.8 mm bilateral holes over the PCC, a 30-G dental needle 
was slowly inserted.  The needle was attached by tubing to Hamilton syringes 
that were placed in a microinjection pump which allowed for precise and slow 
infusions.  Four bilateral injections of sodium azide (3 M sodium azide dissolved 
in phosphate buffer, pH = 7.4, 0.5 µL per injection) were made, alternating left 
and right hemispheres.   Each injection was made over a 10 min period within the 
PCC within the following atlas coordinates (from Bregma, in mm):  A/P -2.8 to -
3.3; M/L ±0.2 to 0.4; D/V -1.2 to -1.3 (Paxinos and Watson, 1997).  The needle 
was left in place for a few minutes after each injection and removed very slowly.  
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Three control animals received phosphate buffer injections in the PCC (vehicle).  
The remaining control rats (n = 9) received the same procedure without drilling or 
injection (sham).  All control animals were under anesthesia for the same amount 
of time as the sodium azide-injected rats (n = 13). 
At the end of surgery, the skin was sutured using 9 mm wound clips 
(Reflex, CellPoint Scientific, Gaithersburg, MD) and treated with a topical 
antibiotic containing pramoxine hydrochloride (Neosporin).  A single 5 mg/kg 
injection of carprofen (Rimadyl, Pfizer) was administered intramuscularly as a 
post-operative NSAID analgesic.  The animal was removed from the anesthesia 
system and allowed to waken, 5–10 min on average.  Upon recovery, the rat was 
moved to its home cage.   
2.3.5  Brain Procedures 
2.3.5.1  Brain Processing 
At the end of the last day of retraining, the brains were removed by rapid 
decapitation, frozen in isopentane, and stored in an ultra-low freezer at -40°C.  
Each brain was sectioned at 40 µM in a -17°C cryostat, collected onto glass 
slides in two series and kept frozen at -40°C until processed.  One series was 
used for histochemical analysis of C.O. activity.  The adjacent series was stained 
with cresyl violet for analysis of cell bodies and cell counting.   
2.3.5.2  Cytochrome Oxidase Histochemistry 
  Experimental slides were processed in batches for enzyme 
histochemistry and each batch included two standard slides.  Standards slides 
contained tissue sections of varying thickness (10, 20, 40, 60, and 80 µm) with 
known C.O. activity and were cut from frozen rat brain homogenate.  The C.O. 
activity of the standards was determined in a previous spectrophotometric 
 38 
experiment.  The standards allow for quantification and comparison among 
batches (Gonzalez-Lima and Jones, 1994; Gonzalez-Lima and Cada, 1998).   
C.O. histochemistry was performed as previously described (Gonzalez-
Lima and Jones, 1994; Gonzalez-Lima and Cada, 1998).  Chemicals were 
purchased from Sigma.  Frozen sections were first incubated at 4°C for 5 min in 
a 0.1 M sodium phosphate buffer (PBS, pH 7.6) solution containing 0.5% 
glutaraldehyde and 9% sucrose, to facilitate adherence to the slides.  This was 
followed by three baths of 9% sucrose in PBS (5 min each) at graded 
temperatures in order to bring the tissue from 4°C to room temperature and to 
remove red blood cells.  Next, the slides were placed in a preincubation bath of 
50 mM Tris buffer that included 0.55 g cobalt chloride, 200 g sucrose, 10 mL 
dimethyl sulfoxide, and 774 mL of 0.1 M hydrochloric acid for 10 min.  Following 
a 5 min rinse in PBS, sections were incubated for 60 min at 37°C in an oxygen-
saturated solution containing 0.35 g 3,3’-diaminobenzidine tetrahydrochloride, 
52.5 mg cytochrome c, 14 mg catalase, 35 g sucrose, and 1.75 mL dimethyl 
sulfoxide in 700 mL PBS.  The reaction was stopped by fixing the tissue in 9% 
sucrose PBS-buffered formalin (4%) for 30 min.  Sections were dehydrated in 
baths of increasing concentrations of ethanol (30, 50, 70, 95, 95, 100, and 100%, 
5 min each), cleared in xylene (3 times, 5 min each), and coverslipped with 
Permount. 
2.3.5.3  Cytochrome Oxidase Image Analysis 
C.O. activity was quantified by optical densitometry using Java software 
(Jandel Scientific) as detailed in Gonzalez-Lima and Cada (1998).  A Kodak 
calibration strip with various gray levels of known optical densities (O.D.) was 
imaged and subsequent measurements were automatically reported to a 
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spreadsheet in O.D.  Tissue sections were placed on a DC-powered lightbox, 
captured with a Javelin analog CCD camera, and digitized with a Targa-M8 
frame-grabber.  The field of view was approximately 0.75 × 1.0 cm.  For each 
area of interest, O.D. was measured bilaterally across three adjacent brain 
sections per subject, using a brain atlas (Paxinos and Watson, 1997) to delineate 
the regions.  For each brain region, the group average was calculated with the 
median value per subject.   
For one standard per batch, ten measurements per thickness were 
measured by image analysis.  Using the mean O.D. values and C.O. activity of 
the tissue standards, O.D. values for each area of interest were converted to 
units of C.O. activity.  The linearity of each batch was verified by regression 
equations (r2 > .90) and calibration curves were calculated under the assumption 
that increased tissue thickness is directly correlated with an increase in 
histochemically-revealed C.O. activity (Gonzalez-Lima and Cada, 1998).  This 
curve predicted C.O. activity from the O.D. measures of the experimental tissues 
within each batch.  The use of individual batch standards and accompanying 
regression curves aided in the control of interbatch variability.  C.O. activity was 
reported as µmol/min/g of tissue. 
Sodium azide is a specific inhibitor of C.O., and since the volume of drug 
injected is small (0.5 µL) and not likely to diffuse substantially, C.O. 
histochemistry also estimated the location of injection.  Metabolic inhibition might 
affect other brain regions that connect with the PCC.  Thus, we examined the 
activity in areas with major efferent and/or afferent connections.  Of the regions 
examined, the anterior thalamic nuclei and the subiculum are the most heavily 
connected to the PCC (Finch et al., 1984; van Groen and Wyss, 1992a; van 
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Groen and Wyss, 2003).  The PCC is a component of the Papez circuit, an 
anatomical pathway connecting many limbic structures that are implicated in 
spatial behavior (Mello e Souza et al., 1999; Harker and Whishaw, 2002; van 
Groen et al., 2004).  Therefore, we also measured activity in this pathway which 
involves the following regions (projections are in brackets):  cingulate cortex 
[cingulum]  entorhinal & perirhinal cortices [perforant pathway]  hippocampal 
proper [alveus]  subiculum [fornix]  mammillary bodies [mamillothalamic 
tract]  anterior thalamic nuclei [anterior thalamic radiation]  cingulate cortex.  
Brain regions will be referred to using the nomenclature from a rat brain atlas 
(Paxinos and Watson, 1997).  The regions of the PCC we sampled are shown in 
Figure 2. 
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Figure 2.2 Coronal brain diagram around Bregma -2.8 mm indicating the 







2.3.5.4  Nissl Staining 
Nissl staining was used to count cell bodies, obtain stereological estimates 
of PCC cell density, and determine if the changes in C.O. activity were due to 
lower enzymatic activity alone or accompanied by neurodegeneration.  For each 
subject, we stained the alternate slide to the one that showed the lowest C.O. 
activity in the PCC.  Frozen brain sections were delipidized in a series of baths:  
95% ethanol, 70% ethanol, distilled water, and 0.05 M sodium acetate buffer (pH 
4) (2.5 min each).  This was followed by staining in 0.1% cresyl violet in sodium 
acetate buffer at 45°C for 4 min, differentiated in 70% and 95% ethanol, and 
dehydrated in sequential baths of 95%, 100% and 100% ethanol (5 min each).  
Slides were then cleared in two washes of xylene (5 min each) and coverslipped 
with Permount. 
2.3.5.5  Posterior Cingulate Cortex Cell Count 
Cell counts were measured by an experimenter who was blind to subject 
assignment.  Cell density (cells/volume) in the PCC was estimated from Nissl-
stained sections of vehicle control (n = 3), sham control (n = 3), and sodium 
azide (n = 6) subjects using the optical dissector stereological method.  The 
imaging setting consisted of a Labophot-2 binocular bright field microscope 
(Nikon Corporation, Tokyo, Japan) connected to a DVC-340 scan camera, 
DVCView 3.3 imaging software (DVC Company, Austin, TX), a Microcode II 
digital readout (Boeckeler Instruments, Inc., Tucson, AZ) and a PC computer.  
Cell density was estimated in three different PCC regions: 1) layers II/III of the 
dorsal PCC, 2) layers V/VI of the dorsal PCC, and 3) layers III/IV of the ventral 
PCC.  Differential cell count was obtained based on morphological criteria for 
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brain cells.  Neurons were identified by large ellipsoidal/pyramidal cell body, low 
nucleus/cytoplasm ratio, heterochromatic nucleus, and visible nucleolus; while 
glia appear with a small cell body, high nucleus/cytoplasm size ratio, and 
hyperchromatic nucleus.  Cells (except those on top of the sections) were 
identified at 50X through the thickness of a section and were counted when they 
first came into focus within an unbiased counting frame (Harding et al., 1994).  
One sample per PCC region was obtained from each of six sections per subject 
within a randomly determined cerebral hemisphere.  PCC cell density per region 
was calculated as Nvcells = ΣQ-/Σv(frame), where ΣQ- is the sum of cell counts per 
sample, and Σv(frame) is the area of the unbiased counting frame (0.0396 mm2, 
adjusted for 140X magnification) multiplied by the length of the analyzed region 
(d).  The length was calculated as d = (No. of sections – 1) x No. of section series 
x section thickness. 
2.3.5.6  Thiobarbituric Acid Reactive Substances Analysis 
Rat brain homogenates were exposed to different concentrations of 
sodium azide and lipid peroxidation was quantified using the thiobarbituric acid 
reactive substances (TBARS) assay as previously reported (Zhang et al., 2006).  
The range of sodium azide concentrations was based on the final concentration 
(100 mM) of 3 M sodium azide after distribution in the PCC volume, which was 
estimated in one of the subjects from C.O. stained sections by means of the 
Cavalieri method.  An array of grid testing points was randomly superimposed 
over a magnified PCC.  The volume was calculated as V = Σ(P) X a(p) X T, 
where Σ(P) is the sum of grid points in the PCC, a(p) is the square of the linear 
distance between points on a grid divided by the square of the magnification, and 
T is the distance between the first and last section containing the PCC.  We 
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determined the VPCC = 29.4 mm3.  Three adult Sprague Dawley male rats (5 
months old) were decapitated, and their brains were quickly extracted and 
homogenized in a glass-glass homogenizer (20–25 strokes).  Homogenates were 
aliquoted in 1.5 mL Eppendorf tubes, slowly frozen in isopentane at -40°C and 
stored until further use.  Freeze-thaw cycles were avoided.  On the day of the 
experiment, homogenates were diluted at 12.5% (w/v) in PBS (pH 7.4 at room 
temperature), vortexed, and kept in ice.  Homogenates were combined with 
sodium azide [0 mM (n = 8), 5 mM (n = 6), 25 mM (n = 2), 50 mM (n = 4) or 100 
mM (n = 4)] and incubated at 37°C in the dark for 1 hr in closed 1.5 mL 
Eppendorf tubes.  After incubation, the proteins were precipitated by the addition 
of 25% trichloroacetic acid (50/50, v/v).  Samples were then vigorously vortexed 
and centrifuged at 10,000 rpm for 30 min at room temperature.  Supernatants 
were combined with 1% thiobarbituric acid in 0.3% NaOH (50/50 v/v) and 
incubated in glass test tubes at 90°C for 40 min.  Samples were then maintained 
at room temperature for 5 min and the absorbances were measured in a 
Shimadzu spectrophotometer at λ = 532 nm using tetraethoxypropane as an 
external standard (ε = 34.5 mM-1 min-1).  The levels of lipid peroxidation were 
expressed as TBARS units (µmol/L). 
2.3.6  Statistical Methods 
Repeated-measures analysis of variance (ANOVA) containing one within-
subject variable (training day) and one between-subject variable (group) was 
used to verify learning performance before surgery.  Matching subjects to 
treatment group based on their training performance prevented pre-treatment 
group differences that might influence their post-treatment performance.   
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The effects of PCC hypometabolism on reference memory during the 
probe task were analyzed using Student’s t test.  Student’s t tests also assessed 
group differences in the following measures of the probe task: total nosepokes; 
initial nosepokes to baited and unbaited holes; repeat nosepokes to baited and 
unbaited holes; total nosepokes to baited and unbaited holes; internosepoke 
interval between baited and unbaited holes; and latency to complete the probe.  
Post-training scores were evaluated with repeated-measures ANOVA followed by 
simple contrasts.   
Group differences in brain C.O. data and cell counts in the Nissl-stained 
slides were examined using Student’s t tests.  Furthermore, the functional 
relationships between the PCC and other brain regions were analyzed by 
computing Pearson product-moment correlations within each group (Nair and 
Gonzalez-Lima, 1999).  Finally, for the TBARS experiment, comparisons were 
made using one-way ANOVA followed by Dunnett’s test for multiple 
comparisons, which compares the mean of each experimental group with the 
mean of the control group.  All statistical testing was carried out using the SPSS 
11.5 software package (SPSS, Inc., Chicago, IL).  Differences were considered 
statistically significant at the two-tailed p < .05 level for all tests.   
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2.4  RESULTS 
2.4.1  Behavioral Analysis 
Two animals were excluded from the experiment.  One was removed 
because it  was not eating upon arrival to the research facility, and another died 
during surgery.  As there was no difference between vehicle and sham control 
groups in reference memory performance in the probe (t(10) = 0.753, p = .469) 
and retraining trials (t(10) = 1.518, p = .160), these rats were treated as a single 
control group for subsequent analysis. 
The reference memory scores during acquisition are similar to what has 
been shown in another study using a similar training paradigm consisting of 4 
trials per day for 7 days (Lannert and Hoyer, 1998).  All rats significantly 
improved reference memory of the baited holeboard over the 8 days of training, 
F(7, 147) = 23.80, p < .001 (Figure 3).  However, there was no effect of group (F(1, 
21) = 0.00, p > .984).  This was expected since the animals were matched into 
treatment groups based on their training performance. 
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Figure 2.3 Acquisition performance in the holeboard.  Means ± S.E.M. of 
reference memory scores of the baited pattern are plotted by day (5 trials/day). 
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During the unbaited probe trial, the reference memory of sodium azide-
injected animals was less than that of control animals (0.27 versus 0.37, 
respectively, Figure 4) (t(21) = -1.671, p > .05).  After comparing each subject’s 
probe scores to their maximum training score, the mean group difference 
approached significance (F(1, 21) = 4.10, p = .056).  When probe scores were 
compared to training averages within each group, only the rats treated with 
sodium azide showed significant impaired memory for the baited pattern in the 
probe trial (Figure 4; t(10) = 5.395, p < .001).  The control group did not show a 
significant decline in memory (t(11) = 1.877). 
In the probe trial, the sodium azide-treated rats spent a longer amount of 
time between the initial pokes into previously-baited holes (t(21) = 2.51, p = .02) 
although the time to complete the trial was not different from control animals 
(t(21) = 2.027).  In addition, the total number of nosepokes of the sodium azide-
treated rats was not different from control rats  (26 versus 23, respectively) (t(21) 
= 0.565).  There were no group differences in the probe trial in the number of 
novel or repeated nosepokes in baited or unbaited holes.   
Analysis of daily retraining averages by repeated measures did not reveal 
a significant effect of day or group.  In addition, there were no group differences 
when daily retraining averages were analyzed with Student’s t test.  Therefore, 
sodium azide-treated rats recovered to control levels with continued training over 
days 13–16 (Figure 4). 
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Figure 2.4 Mean ± S.E.M. of reference memory before (training) and after 
(probe and retraining) sodium azide injection into the PCC.  *significantly different 









































2.4.2  Brain Findings 
2.4.2.1  Cytochrome Oxidase Histochemistry 
Optical density of the selected regions of interest was converted to 
enzyme activity units (Table 2).  Out of 26 regions examined, the only area to 
show a group difference was the PCC (t(21) = 4.165, p < .001).  Further 
examination of this area revealed that hypometabolism due to sodium azide in 
the PCC was specific to the dorsal aspect of the PCC (Figure 5; t(21) = 5.601, p 
< .001).  The rats injected with 3 M sodium azide showed a 23% decrease in 
C.O. activity in the dorsal PCC five days after administration.  Significant 
decreases in activity were found from Bregma -2.3 to -4.2 mm, confirming that 
our injection was within the boundary of the PCC. 
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Table 2.2 Regional differences in cytochrome oxidase activity (MEAN ± S.E.M. 
µmol/min/g) in brains of rats injected with sodium azide in the PCC or sham 
control. 
 
AREA OF INTEREST CONTROL AZIDE
abbreviation Bregma level (mm) Mean ± SEM (n) Mean ± SEM (n)
CINGULATE REGIONS
      posterior cingulate PCC 270 ± 6 (12) 233 ± 7 (11) *
          dorsal PCC RSA -1.80 to -5.30 264 ± 5 (12) 204 ± 10 (11) *
          ventral PCC RSG -1.80 to -5.30 276 ± 7 (12) 263 ± 4 (11)
      anterior cingulate ACC  1.60 to -1.40 251 ± 3 (10) 260 ± 5 (9)
      cingulum bundle cb -1.80 to -5.30 33 ± 3 (12) 29 ± 3 (11)
THALAMIC REGIONS
      anterior dorsal AD -1.80 453 ± 16 (11) 451 ± 19 (11)
      anterior ventral AV -1.80 349 ± 5 (11) 338 ± 11 (11)
      anterior medial AM -1.80 275 ± 5 (11) 262 ± 9 (11)
      reticular Rt -1.80 299 ± 5 (11) 303 ± 8 (11)
      rhomboid/reuniens Rh/Re -1.80 250 ± 10 (11) 246 ± 6 (11)
      lateral dorsal LD -2.30 298 ± 12 (12) 292 ± 12 (11)
HIPPOCAMPAL FORMATION
anterior/dorsal
      CA1 CA1d -3.80 236 ± 7 (12) 227 ± 7 (11)
      CA3 CA3d -3.80 221 ± 6 (12) 216 ± 8 (11)
      dentate gyrus DGd -3.80 306 ± 7 (12) 292 ± 11 (11)
posterior/ventral
      CA1 CA1v -5.30 253 ± 8 (12) 252 ± 8 (11)
      CA3 CA3v -5.30 277 ± 10 (12) 273 ± 11 (10)
      dentate gyrus DGv -5.30 226 ± 8 (12) 230 ± 7 (11)
      subiculum SUB -5.30 226 ± 13 (11) 241 ± 10 (11)
      mammillary bodies MB -4.80 356 ± 15 (11) 350 ± 13 (9)
      entorhinal Ent -4.80 148 ± 12 (12) 142 ± 11 (11)
      perirhinal PRh -4.80 175 ± 12 (12) 165 ± 12 (11)
OTHER
secondary motor cortex M2 -0.26 276 ± 8 (10) 279 ± 8 (9)
secondary visual cortex
      medial area V2M -5.30 253 ± 9 (12) 251 ± 8 (11)
      lateral area V2L -5.30 260 ± 8 (12) 254 ± 5 (11)
caudate putamen CPu -1.80 295 ± 6 (12) 280 ± 7 (11)
zona incerta ZI -3.80 219 ± 12 (12) 207 ± 14 (11)
periaqueductal gray PAG -5.30 269 ± 12 (10) 271 ± 10 (10)
raphe nuclei RLi -5.30 292 ± 11 (10) 303 ± 8 (10)
*signficantly different from control (p < 0.001 )
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Figure 2.5 Illustrations of cytochrome oxidase-stained brain sections around 
Bregma -2.80 mm.  These were obtained from rats that received either vehicle 








 2.4.2.2  PCC-Interregional Correlations 
Correlations in C.O. activity between the PCC and other brain regions 
were different in the two groups.  In the control group, there were nine significant 
correlations (p < .05) in C.O. activity between the PCC and other regions of 
interest (Table 3).  An interesting finding is the number of positive correlations (n 
= 6) between the PCC and hippocampal areas (DGv, CA1v, CA3v, SUB, PRh, 
and Ent).  Significant positive correlations were also found with the CPu and 
secondary visual areas (V2M, V2L).  In the sodium azide-treated group, there 
was only one significant correlation—one negative correlation between the PCC 
and CA3d.  The positive correlations in the control group between C.O. activity in 
the PCC and other regions revealed functional coupling that was absent in the 
sodium azide-treated group.  This suggests that these regions were functionally 
dissociated in sodium azide-treated subjects. 
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Table 2.3 Significant Pearson correlation coefficients (r) of C.O. activity 
between the PCC and other brain regions. 
 
PCC–Interregional Correlations
       CONTROL
CA3d 0.19   -0.66 *
CA1v 0.60 * -0.16
CA3v 0.71 * 0.02
SUB 0.67 * 0.28
PRh 0.63 * 0.01
Ent 0.64 * 0.09
DGv 0.86 * 0.49
CPu 0.64 * -0.05
V2M 0.77 * 0.39
V2L 0.73 * 0.04
*significantly different from zero (p < 0.05)
        AZIDE
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2.4.2.3  PCC Cell Count 
There were no significant differences in neuronal or glial cell density 
between vehicle control versus sham control rats (p > .05).  Therefore, their 
scores were pooled for the following analysis.  The neurotoxic effect of sodium 
azide in PCC was evidenced by dramatic changes in both neuronal and glial cell 
density.  Sodium azide induced significant decreases in neuronal density and 
increases in glial cell density in all the analyzed PCC regions as compared to 
control animals (Figure 6, p < .05).  The largest effect was observed in the ventral 
PCC where sodium azide produced a 64.3% decrease in neuronal density and a 
4.8-fold increase in glial cell density (Figure 7).  Furthermore, the majority of the 
remaining PCC neurons in sodium azide-treated subjects showed morphological 




Figure 2.6 Neuronal and glial cell densities in the PCC in sodium azide-





































Figure 2.7 Cresyl violet-stained cells in the dorsal PCC (A) and ventral PCC 
(B) from rats with vehicle (left) or sodium azide injections (right).  Sodium azide 
significantly increased gliosis and neuronal loss.  Scale bar = 10 µm. 
 
















2.4.2.4  Oxidative Stress 
Sodium azide potently increased brain lipid peroxidation in a 
concentration-dependent fashion (F(4, 23) = 12.8, p < .001).  Compared to control, 
a seven-fold increase in lipid peroxidation was produced by the sodium azide 
concentration estimated in the PCC in the in vivo experiment (100 mM).  A 
concentration twenty times lower (5 mM) produced a two-fold increase in lipid 
peroxidation (Figure 8). 
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Figure 2.8 Sodium azide treatment increases lipid peroxidation.  Data 
represent the Mean ± S.E.M. of TBARS reaction product in rat brain 

























2.5  DISCUSSION 
The present study confirms that the PCC is involved in spatial memory 
and verified that a local injection of sodium azide in this region induces 
neurotoxicity that is associated with inhibition of mitochondrial metabolism and 
oxidative damage.  A major finding is that isolated hypometabolism in the PCC 
due to sodium azide treatment produced memory impairment in a holeboard task 
that required using spatial cues.  The deficits in the probe trial are unlikely due to 
a change in response to sucrose reward.  Rats with excitotoxic lesions in the 
PCC were not different from control animals in a sucrose consumption test 
(Bussey et al., 1996).  Also, previous studies have shown that rats treated 
systemically with sodium azide have no change in sensory or motor function, or 
in exploratory activity in an open field chamber (Bennett and Rose, 1992; 
Szabados et al., 2004).  However, they did have impaired memory for spatial 
tasks such as the eight-arm radial maze (Bennett and Rose, 1992), Morris water 
maze (Bennett et al., 1992), and holeboard task (Callaway et al., 2002).  The 
present study did not find a difference in the total number of nosepokes between 
sodium azide-treated and control rats, which suggests that the impaired 
performance was due to a deficit in memory retrieval for the baited pattern and 
not due to differences in general activity or motivation.   
The fact that sodium azide-treated rats were not different from control rats 
during the retraining phase in the holeboard maze may be due to the availability 
of a competing learning process.  The baited pattern could be learned either by 
forming and accessing a cognitive map, or by response/procedural learning 
(Whishaw et al., 2001).  In the present study, subjects were placed in the same 
corner of the holeboard for every trial and thus, rats using a response/procedural 
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strategy would also exhibit similar performance.  Brain systems consisting of 
different structures are involved in processes for similar types of learning and 
memory (“parallel processing”) (Lee and Kesner, 2003; McIntyre et al., 2003; 
Mizumori et al., 2004).  Which neural system has more relative influence on 
behavioral expression may vary depending upon a number of factors such as 
age, experience, or incentive.  If the PCC is damaged, the tendency to use 
cognitive maps is removed and the competing response/procedural learning may 
proceed.  Furthermore, C.O. inhibition in the PCC was not comprehensive.  
Similar performance in the two groups during retraining may have resulted from 
the spared ventral portion of the PCC.  Finally, the most anterior and posterior 
aspects of the PCC were also spared from the inhibitory metabolic effects of 
sodium azide, and some components of the stored information may have 
remained undisturbed.  It is possible that the metabolically-normal tissue was 
sufficient for retraining in the maze. 
C.O. histochemistry verified that the hypometabolism was localized in the 
PCC and that significant denervation of connecting structures did not occur by 
five days after sodium azide administration.  The observation of hypometabolism 
in the dorsal, but not ventral aspect of the PCC can be explained by the depth of 
injection during surgery.  We wanted our lesion to be specific to the PCC and 
avoid damage to the underlying cingulum fiber bundle.  There is debate in the 
animal literature that previous findings of behavioral impairment from PCC 
damage can be, in part, due to inadvertent damage to this fiber tract (Neave et 
al., 1994; Warburton et al., 1998). 
Correlations in metabolic activity between PCC and other brain regions 
were analyzed.  Interestingly, most of the significant correlations found in the 
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control animals were in the Papez circuit (DGv, CA1v, CA3v, SUB, PRh, and 
Ent).  This circuit was originally hypothesized to underlie emotion (Papez, 1937).  
It has been modified to include memory because lesions of these structures in 
humans and rodents often lead to disruption in learning and memory (Valenstein 
et al., 1987; Holdstock et al., 2000; Harker and Whishaw, 2002; van Groen et al., 
2004).  The PCC-interregional correlations validate the idea that decreasing the 
functional relationships in the Papez network can impair memory.  PCC 
hypometabolism by sodium azide eliminated all the significant correlations 
between the PCC and other brain regions that were found in the control group. 
The dose of sodium azide used in this study (3 M) was sufficient to 
produce memory impairment that was accompanied by cellular changes such as 
decreased C.O. activity and increased oxidative damage.  Brouillet et al (1994) 
previously determined that a 3M intrastriatal injection of sodium azide 
significantly increased lactate and decreased ATP concentrations after 3 hours 
(Brouillet et al., 1994).  These alterations may have led to the neurodegenerative 
effects we observed in the Nissl-stained tissue; specifically, there were significant 
decreases in neurons and increases in glial cells. 
We also showed that lipid peroxidation, a marker of oxidative stress, is 
increased in sodium azide-treated brain homogenates.  A defect in mitochondrial 
metabolism increases the generation of reactive oxygen species.  Increasing 
evidence implicates oxidative damage in the neurodegenerative process of 
Alzheimer’s disease (AD) (Benzi and Moretti, 1995; Reddy and Beal, 2005; 
Mielke and Lyketsos, 2006).  Sodium azide-induced lipid peroxidation may 
represent a pharmacological research tool to study oxidative stress associated 
with neurodegenerative diseases and aging. 
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The PCC may be a vulnerable brain region.  The PCC has a high baseline 
activity in healthy human subjects (Minoshima et al., 1997) and it contains 
numerous glutaminergic excitatory synapses.  To fulfill a high energy demand, 
C.O. expression is upregulated (Wong-Riley et al., 1998).  A high energy demand 
will render the PCC vulnerable to other metabolic insults such as vascular 
problems or C.O. inhibition.  In rats, systemic administration of an N-methyl-D-
aspartic acid (NMDA) antagonist produces region-specific neurotoxicity, and the 
PCC is the most affected region (Li et al., 2002).  Likewise, the PCC would be 
one of the first areas affected by C.O. inhibition that compromises energy 
generation and eventually cell survival.    
The PCC displays the largest decrement in glucose utilization in early-
stage Alzheimer’s disease (Minoshima et al., 1997).  Laminar analysis of C.O. 
activity in the PCC from AD patients reveals a greater decrease in the energy-
demanding superficial layers that contain synaptic neuropil (Valla et al., 2001).  
PCC hypometabolism appears before the onset of memory deficits in persons at 
genetic risk for AD, but who are not yet cognitively impaired (Reiman et al., 
1996), as well as in subjects with mild cognitive impairment who later develop AD 
(Mosconi, 2005). 
PCC hypometabolism by sodium azide-induced inhibition of C.O. activity 
is a good model to study early AD pathophysiology, as confounds from 
neurotransmitter-specific lesions are eliminated.  C.O. inhibition in the PCC 
changed interregional correlations in brain activity and increased oxidative stress, 
which resulted in memory impairment in a spatial holeboard task.  AD patients 
show disrupted correlations in metabolism between cortical regions (Horwitz et 
al., 1987).  Therefore, sodium azide-treated rats are a useful model for 
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characterizing behavior and brain impairments associated with brain metabolic 
deficits, and for testing potential memory-enhancing drugs.  Future studies will 
test if methylene blue, a metabolic enhancer (Callaway et al., 2004) and inhibitor 
of neurodegeneration (Zhang et al., 2006), can prevent the deficits caused by 
sodium azide-induced hypometabolism in the PCC. 
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CHAPTER 3:  Memory Facilitation by Methylene Blue: Dose-
dependent Effect on Behavior and Brain Oxygen Consumption 
 
3.1  ABSTRACT 
Methylene blue (MB) administered post-training improves memory 
retention in avoidance and appetitive tasks, and restores spatial memory 
impaired by an inhibitor of cytochrome oxidase.  MB may improve memory 
retention by increasing brain oxygen utilization.  We investigated which doses 
improve memory without nonspecific behavioral effects and whether MB 
enhances brain oxygen consumption.  Different doses were evaluated 24 h after 
administration in the following tasks:  wheel running, feeding, open field 
habituation, and object recognition tests.  The 1–10 mg/kg MB-treated rats were 
not different from saline-treated rats in locomotion or feeding behavior.  The 50–
100 mg/kg doses decreased feeding and running wheel behavior.  The 4 mg/kg 
dose improved behavioral habituation and object memory recognition.  Dose-
dependent effects of MB on brain oxygen consumption revealed that low 
concentrations increased brain oxygen consumption in vitro and 24 h after in vivo 
administration.  Therefore, MB doses that facilitate memory retention are 
associated with increased brain oxygen consumption.
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3.2  INTRODUCTION 
Memory difficulties in dementia are correlated with impaired mitochondrial 
oxidative metabolism and brain oxygen utilization (de la Torre, 2004; Beal, 2005).  
Therefore a drug that increases brain mitochondrial respiration may improve 
memory.  One candidate is methylene blue (MB), a redox compound with an 
affinity for mitochondria (Visarius et al., 1999).  After in vivo administration, MB 
passes the blood-brain barrier and accumulates in the human brain within hours 
(Peter et al., 2000).  MB increases cytochrome oxidase (C.O.) activity by 
donating electrons to the electron transport chain (Scott and Hunter, 1966; 
Callaway et al., 2004).   
The memory-improving action of MB was first reported by Martinez et al. 
(1978).  A low dose (1 mg/kg) injected in rats post-training enhanced retention of 
an inhibitory avoidance response when tested 24 h later (Martinez et al., 1978).  
Our laboratory also examined the effects of low dose MB (1 mg/kg and 4 mg/kg) 
in other appetitive and aversive tasks, and we have provided convincing 
evidence that MB improves memory retention (Callaway et al., 2002; Callaway et 
al., 2004; Gonzalez-Lima and Bruchey, 2004).  Furthermore, Gonzalez-Lima and 
Bruchey (2004) found that rats injected with one or five daily injections of 4 mg/kg 
MB were not different from saline-treated rats in measures of exploration or 
anxiety in an open field chamber.  However, these studies did not evaluate other 
behavioral effects of MB which could explain their results. For example, MB could 
simply modify baseline levels of locomotor activity and thereby increase inhibitory 
avoidance responses. 
Although low dose MB improves memory in various tasks, it has not been 
evaluated for its effects on locomotor activity and feeding behavior that may 
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contribute to the modification of behavior observed in previous avoidance and 
appetitive tasks.  For that reason, our first objective was to investigate which MB 
doses improve behavioral habituation and recognition memory 24 h after 
administration without nonspecific effects on behavior.  Different doses were 
evaluated in wheel running, feeding, open field habituation, and object 
recognition tests.  The first two tests measured locomotion and feeding of a 
sweet cookie.  The second two tests measured between-days memory retention 
of habituation of exploratory behavior (Cerbone and Sadile, 1994) and object 
recognition memory (Lebrun et al., 2000). 
C.O. is the terminal enzyme mediating oxygen utilization (Gonzalez-Lima 
and Cada, 1998).  We previously demonstrated that brain C.O. activity increases 
24 h after 1 mg/kg MB administration in vivo (Callaway et al., 2004).  Improved 
cellular respiration in the brain would explain the enhanced memory retention 
seen in animals after treatment with low dose MB (Martinez et al., 1978; 
Callaway et al., 2002; Callaway et al., 2004; Gonzalez-Lima and Bruchey, 2004).  
However, there are no studies demonstrating a direct action of MB on brain 
oxygen utilization. 
Therefore, our second objective was to investigate brain oxygen 
consumption after in vitro administration of low concentrations of MB (0.5, 5, and 
10 µM) to rat brain homogenates.  These in vitro concentrations correspond to 
the 1–4 mg/kg doses (Peter et al., 2000) that improve memory retention 
(Martinez et al., 1978; Callaway et al., 2002; Callaway et al., 2004; Gonzalez-
Lima and Bruchey, 2004).  A final experiment measured oxygen metabolism in 
rat brains 24 h after in vivo treatment with 1 mg/kg MB.  There is a tight coupling 
between oxygen consumption and neuronal activity (Sokoloff, 1989).  Measuring 
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brain oxygen consumption could help to understand the cellular mechanisms 
underlying the effect of MB on memory. 
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3.3  METHODS 
3.3.1  Subjects 
The experiments were performed in accordance with NIH guidelines for 
the use of experimental animals and were approved by the University of Texas 
Institutional Animal Care and Use Committee.  All rats were purchased from 
Harlan (Houston, TX).  They were housed on a 12 h light-dark cycle with food 
and water access ad libitum.  For the behavioral experiments, subjects were 36 
male Long-Evans rats weighing an average of 366 ± 14 g at the beginning of 
behavioral testing.  An additional ten 7-month old male Long-Evans rats were 
used for the in vitro oxygen assays. 
A previous study indicated that 1 mg/kg MB increased in C.O. activity 24 h 
after administration in Sprague Dawley rats (Callaway et al., 2004).  Therefore, 
twenty-two adult male Sprague Dawley rats weighing an average of 276 ± 2 g 
were used to determine if the C.O. increase 24 hr after MB treatment is related to 
an increase in oxygen consumption in vivo. 
3.3.2  MB Administration 
Rats were counterbalanced into five treatment groups of saline, 1, 4, 10, 
or 100 mg/kg MB (Faulding Pharmaceuticals, Paramus, NJ).  The injections were 
performed intraperitoneally (ip).  All behavioral experiments were conducted 
during the light phase.  Behavior was measured 24 h after MB administration with 
the exception of the running wheel, which lasted for a continuous 24 h period. 
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3.3.3  Behavioral Procedures 
 3.3.3.2  Running wheel 
Rats were injected with MB or saline, and placed in the holding 
compartment of a standard activity wheel.  The door between the holding cage 
and wheel remained open to allow access to food and water ad libitum.  The 
number of revolutions was recorded 24 h later. 
 3.3.3.3  Feeding test 
Before the feeding experiment, rats were given vanilla wafers (Nabisco 
Brands, Inc., East Hanover, NJ) in their home cage in order to avoid neophobia.  
Rats were injected with MB or saline 24 h before testing.  Trials were conducted 
in a box (43.2 cm X 21.6 cm X 30.5 cm) with clear plastic sides.  One vanilla 
wafer softened with approximately 5 mL of distilled water was placed in a plastic 
weigh boat on a wire mesh floor.  Subjects were placed in the box facing the 
wafer and the experimenter left the room.  The rats were removed after 5 min 
and the remaining wafer weight was recorded.  Scattered food was collected and 
included in the calculations. 
 3.3.3.4  Open field Habituation Test 
An automated activity monitoring system from MED Associates (St. 
Albans, VT) recorded various motor indices of exploration.  The 43.2 cm2 
chamber consisted of clear plastic sides 30.5 cm high and a plexiglass floor.  
Activity was detected by parallel beam arrays of infrared motion detectors (16 X 
16, 2.5 cm apart).  Two arrays located 2.5 cm above the floor detected 
ambulatory and stereotypic measures, and a third array positioned 17.2 cm 
above the chamber floor detected rearing.  The measures included ambulatory 
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counts, time, and distance (number of horizontal beam breaks, and the 
calculated time and distance traveled); stereotypic time and counts (duration and 
frequency of short movements without ambulation of the rat, including grooming, 
turning, and tailflick behavior); vertical counts and time (frequency and duration 
of vertical beam breaks, which were produced by rearing on hindlimbs); resting 
time (time spent with no new beam breaks); and center crossings (number of 
crossings into the central 38% area of the open field). 
Exploratory behavior was assessed in a dimly-lit, sound-proofed testing 
room.  Rats were habituated to the room for a 5 min period.  They were then 
placed in the chamber facing one corner and their behavior was recorded for 5 
min.  Immediately after the session, they were administered MB or saline and 
returned to their home cage for 24 h.  The following day, the rats received 
another 5 min habituation period in the testing room followed by a second 5 min 
session in the open field chamber.  The chambers were cleaned with a mild 
detergent between animals (Bio-Clean, Stanbio Laboratories, Boerne, TX). 
 3.3.3.5  Object Recognition Test 
Previous studies of the object recognition test indicate that a 24 h intertrial 
interval results in loss of memory for the object (Bartolini et al., 1996; Pitsikas et 
al., 2002).  Therefore, we expected that saline-treated rats would explore the 
objects equally and that MB would improve memory for the familiar object on day 
2.  The object recognition test was conducted in the same chamber used for the 
open field test.  Since all animals previously received two days of 5 min open 
field trials, they were already familiar with this environment and did not require 
more pre-exposure.  The objects were unopened aluminum cola cans, large 
metal clamps, and 50 mL clear centrifuge tubes filled with blue paper.  The 
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objects were suspended so as to not interfere with the infrared beams or be 
displaced by the animals.  The MED Associates activity monitoring program 
recorded time near the object, which was defined as the time spent in the corner 
(10 X 10 cm corner area) where the objects were suspended. 
The first day consisted of a 3 min trial in which animals freely explored two 
identical objects that were suspended in opposite corners of the open field.  The 
arena was cleaned with diluted Bio-Clean between each trial and the objects 
were wiped with 70% ethanol to minimize olfactory cues.  Immediately following 
the exploratory session, subjects were returned to their home room and injected 
with MB or saline.  After 24 h, rat received a second trial.  They were placed in 
the same open field except that one object from day 1 was replaced with a novel 
object.  Animals were allowed to explore both objects for 3 min.  Object 
recognition was analyzed using the difference in time spent near the novel 
versus familiar object. 
3.3.4  Brain Oxygen Assays 
 3.3.4.1  Fiber Optic Oxygen Sensor 
Dissolved oxygen concentration was measured with a fiber optic oxygen 
sensor system (Ocean Optics, Dunedin, FL).  The system is as accurate as 
polarographic techniques and it has a faster response time but it does not 
consume oxygen or require frequent calibrations (Shaw et al., 2002).  It consists 
of a fluorescence probe connected to a light source and spectrometer.  Ocean 
Optics software converts partial pressure in the tissue samples to molar 
percentage.  The sensor was calibrated at Ocean Optics and a single-point 
update was completed immediately before the study in a 37°C incubator. 
 73 
  3.3.4.2  in vitro Procedures 
The dose-dependent effects of MB on oxygen metabolism were studied 
using different MB concentrations added to rat brain homogenates.  MB enters 
cellular membranes after it is reduced to leucomethylene blue (LMB) by the 
capillary endothelium (Merker et al., 1997); therefore, LMB was used to facilitate 
entry into the cells in the brain homogenates in vitro.  MB was reduced with 45 
mM ascorbic acid in distilled water and a minimal amount (< 2 mM) of HCl was 
added to speed the reaction (Snehalatha et al., 1997; Mowry and Ogren, 1999).  
Three LMB concentrations were used (0.5, 5.0, and 10.0 µM) that approximated 
the levels found in plasma after a single 100 mg intravenous injection in humans 
(Peter et al., 2000).  Samples were run 9 times per concentration in a counter-
balanced approach. 
The brain homogenization and in vitro procedures were similar to those in 
a previous study (Callaway et al., 2004).  Following decapitation, the brains were 
quickly extracted, mixed thoroughly to form one homogenate, divided into 
centrifuge tubes, spun briefly at a low rpm, and frozen in isopentane.  On the day 
of the assay, the homogenized brains were mixed in isolation buffer (0.32 M 
sucrose, 1 mM EDTA, 8.4 mM Trizma HCl, and 1.6 mM Trizma base) to produce 
a 20% tissue mixture.  To solubilize membranes, 10% deoxycholate was added 
for a final concentration of 0.25% tissue and 0.5% deoxycholate. 
LMB (990 µL) was warmed to 37°C.  Ten microliters of tissue solution 
were added, inverted twice to mix, and placed in a 37°C chamber for 5 min 
measurements.  Control samples contained 10 µL of tissue solution and 990 µL 
of 0.05 M potassium phosphate buffer (0.02 M KH2PO4 and 0.24 M Na2HPO4).  
All final solutions had a pH of 7.2 ± 0.1. 
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 3.3.4.3  in vivo Procedures 
Rats were injected with 1 mg/kg MB ip and killed 1 h (n = 5), 2 h (n = 5), or 
24 h (n = 6) later.  Controls subjects (n = 6) were rats that received an equivalent 
volume of saline intraperitoneally and killed 2 h later.  Following decapitation, the 
brains were quickly extracted, homogenized, frozen in isopentane, and stored at 
-40°C.  For each subject, approximately 50 µL of brain tissue homogenate was 
placed in a microcentrifuge tube, warmed to 37°C in a water bath, and placed in 
a 37°C incubator for analysis.  Each sample was measured for 5 min with the 
oxygen sensor described above. 
3.3.5  Statistical Methods 
SPSS software (version 11.5, SPSS, Chicago, IL) was used for all 
statistical analysis.  Parametric data were analyzed using analysis of variance 
(ANOVA) to test the significance of mean group differences for the open field 
measures and oxygen probe data.  This was followed by Dunnett’s post-hoc t 
tests to compare each treatment group to the control group.  Nonparametric data 
from the running wheel and feeding tests were analyzed with Mann–Whitney U 
tests for independent group mean comparisons.  The Wilcoxon signed-ranks test 
was used for paired data in the object recognition test.  The specific tests and 
two-tailed p levels are reported in the results.  Comparisons were considered 
significant at the p < .05 level. 
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3.4  RESULTS 
3.4.1  Behavioral Effects of MB 
 3.4.1.1  General Observations after in vivo Administration 
Shortly after injection, the 100 mg/kg dose produced piloerection and 
uncoordinated movement in the first three subjects injected.  One of these rats 
was found dead in the running wheel the following day.  This dose was 
discontinued from further use and the other two rats injected with 100 mg/kg 
were excluded from further testing.  Three subjects injected with 50 mg/kg were 
examined in the running wheel and wafer feeding tests.  However, because of 
decreased daily food consumption in these rats, they were excluded from the 
open field habituation and object recognition tests.  The rats injected with saline 
or 1–10 mg/kg MB did not show adverse effects from the injections. 
 3.4.1.2  Running Wheel and Feeding Tests 
Group differences were examined with Mann–Whitney U tests, comparing 
each MB group to the saline-treated group (Table 1).  In the running wheel, rats 
given the highest doses of MB (50 and 100 mg/kg) were significantly less active 
than saline-treated rats, as indicated by fewer median revolutions (35 versus 
279, respectively) (U(14) = 9.0, p = .038).  Rats treated with 1–10 mg/kg MB 
were not different from saline-treated rats in the running wheel. 
In the feeding task, 1–10 mg/kg MB-treated rats ate a similar amount of 
wafer as those treated with saline.  However, the rats injected with 50 mg/kg only 
ate an average of 0.03 g versus a 0.52 g average in the other groups.  Due to the 
small sample size in the 50 mg/kg group (n = 3), the group difference was not 
significant (U(14) = 5.0, p = .088). 
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Table 3.1 Running wheel and feeding test results 24 h after saline or MB 
treatment. 
 
Running Wheel (revolutions) Feeding Test (grams)
MB Dose Mean ± S.E.M. Median Range Mean ± S.E.M. Median Range
(mg/kg) n n
saline 11 318 ± 72 279 28 – 718 11 0.60 ± 0.23 0.10 0 – 1.8
1 4 166 ± 104 92 9 – 470 6 0.48 ± 0.30 0.48 0 – 1.8
4 5 453 ± 112 362 253 – 843 6 0.48 ± 0.28 0.48 0 – 1.5
10 7 268 ± 97 103 78 – 761 7 0.53 ± 0.31 0.53 0 – 1.7
50 3 64 ± 46 35 3 – 154 3 0.03 ± 0.04 0.03 0 – 0.1
100 2 116 ± 111 116 5 – 227





 3.4.1.3  Open Field Habituation Test 
No significant group differences were found on day 1 using ANOVA (Table 
2).  Previous studies suggest that decreased exploratory activity in a familiar 
environment is indicative of habituation (for review, see Cerbone and Sadile, 
1994).  On day 2, 24 h after MB or saline treatment, 4 mg/kg-treated rats were 
less ambulatory (15 ± 3 s) as compared to saline-treated rats (27 ± 2 s).  
Dunnett’s-corrected comparisons verified that 4 mg/kg MB-treated rats showed 
significantly less ambulatory time (p = .006), ambulatory distance (p = .029), and 
ambulatory counts (p = .034) as compared to saline-treated rats.  Likewise on 
day 2, 4 mg/kg MB-treated rats rested longer than saline-treated rats (F(3, 24) = 
6.43, p = .025).  The habituation effect was confirmed as a between-days 
difference in ambulatory distance by accounting for baseline performance on day 
1 (F(3, 24) = 3.02, p = .049).  Percent decreases from day 1 to day 2 in ambulatory 
distance were 5% for saline-treated rats, 18% for 1 mg/kg MB-treated rats, and 
26% for the 4 mg/kg MB-treated group.  The 10 mg/kg MB group showed a 25% 
increase, but it was not statistically significant.  No significant group differences 
were found in measures of rearing (vertical time or counts) on day 2.  In addition, 
there were no group differences in the number of crossings into the center of the 
chamber.  This signifies that MB did not affect center avoidance, an indicator of 
anxiety. 
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Table 3.2 Means + S.E.M. of activity measures in 5 min open field sessions 




MEASURE Day 1 Day 2 Day 1 Day 2
Ambulatory distance (cm) 1343 ± 135 1268 ± 114 1558 ± 102 1277 ± 80
Ambulatory time (s) 26 ± 3 27 ± 2 31 ± 3 27 ± 2
Ambulatory counts 585 ± 70 605 ± 70 715 ± 58 578 ± 49
Vertical time (s) 54 ± 5 55 ± 8 46 ± 9 34 ± 5
Vertical counts 38 ± 3 31 ± 3 38 ± 3 27 ± 5
Stereotypic time (s) 82 ± 4 73 ± 3 84 ± 3 76 ± 5
Stereotypic counts 1455 ± 90 1249 ± 67 1521 ± 53 1336 ± 97
Resting time (s) 188 ± 6 196 ± 5 179 ± 4 194 ± 5
Center crossings 128 ± 17 120 ± 15 131 ± 5 107 ± 8
(38% of chamber)
4 mg/kg 10 mg/kg
MEASURE Day 1 Day 2 Day 1 Day 2
Ambulatory distance (cm) 1123 ± 126 828 ± 152 * 1259 ± 253 1572 ± 82
Ambulatory time (s) 22 ± 3 15 ± 3 * 25 ± 5 33 ± 3
Ambulatory counts 494 ± 54 354 ± 75 * 569 ± 126 715 ± 56
Vertical time (s) 71 ± 12 60 ± 16 43 ± 9 52 ± 5
Vertical counts 49 ± 8 33 ± 8 40 ± 9 40 ± 4
Stereotypic time (s) 75 ± 5 64 ± 4 77 ± 7 81 ± 3
Stereotypic counts 1300 ± 108 1085 ± 89 1345 ± 142 1454 ± 75
Resting time (s) 199 ± 7 218 ± 7 * 193 ± 14 181 ± 3
Center crossings 131 ± 18 95 ± 22 133 ± 23 150 ± 7
(38% of chamber)
*significantly different from saline, p < .05
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3.4.1.4  Object Recognition Test 
There were no significant differences in the amount of time rats spent 
exploring each identical object on day 1.  On day 2, all rats distinguished 
between the two objects as shown by a longer exploration time with the novel 
object (p = .002, Wilcoxon signed-ranks test).  Day 2 group averages (Table 3) 
showed that saline-treated rats explored the novel object 5 sec longer than the 
familiar object.  The effects of MB on object recognition varied in a dose-
dependent manner.  On average, rats treated with 1 mg/kg MB explored the 
novel object 2 s longer than the familiar object, the 4 mg/kg MB-treated rats 
spent almost 10 s more exploring the novel object, and the 10 mg/kg MB-treated 
group spent 16 s longer in close proximity to the novel object.  The 4–10 mg/kg 
MB-treated groups showed a statistically reliable difference (both groups:  p = 
.028, Wilcoxon signed-ranks test). 
 
 
Table 3.3 Dose-response effects of MB on object recognition memory. 
MB dose   Familiar Object   Novel Object
(mg/kg) n Mean ±S.E.M. Mean ±S.E.M.
0 10 5.01 ±1.45 10.06 ±2.45
1 6 6.65 ±1.41 8.65 ±3.12
4 6 3.63 ±1.36 13.16 ±4.58
10 6 1.93 ±0.83 17.55 ±12.46





3.4.2  Effects of MB on Brain Oxygen Consumption 
 3.4.2.1  Dose-dependent Effects after in vitro Administration 
The values obtained from our control group indicated a partial pressure 
baseline measure of 28 mmHg, which is consistent with other studies of brain 
oxygen tension (Doppenberg et al., 1998; Duong et al., 2001).  Repeated-
measures ANOVA demonstrated that oxygen concentration decreased over time 
in all groups (Figure 1; F(4, 128) = 712.96, p < .001).  This was expected because 
respiratory substrates were not added to the samples and, therefore, 
consumption occurs only to the extent of the oxygen concentration in the 
samples.  There was a main effect of LMB (F(3, 32) = 10.18, p < .001, repeated-
measures ANOVA).  Dunnett-corrected comparisons showed significant 
differences between control and 5 µM LMB (p = .004), and control and 10 µM 
LMB (p < .001).  The difference in starting points suggests that LMB increases 
oxygen metabolism within the first min post-administration in vitro. 
 
 81 
Figure 3.1 Effects of LMB on brain oxygen consumption in vitro.  *significantly 
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 3.4.2.2  Time-dependent Effects after in vivo Administration 
There was a significant effect of time after MB administration on oxygen 
consumption (F(3, 18) = 9.59, p = .001, repeated-measures ANOVA).  Brain 
oxygen concentration was significantly lower 24 h after treatment with MB versus 
saline (Dunnett’s p = .001).  There were no differences 1 or 2 h following MB 




Figure 3.2 Effects of 1 mg/kg MB on brain oxygen consumption at 1, 2, and 24 





























3.5  DISCUSSION 
This study was the first to determine that low dose MB improves between-
days memory retention in habituation and object recognition tasks without 
nonspecific effects on motor activity, feeding, and anxiety.  It is also the first to 
demonstrate that MB enhances brain oxygen consumption.  Previous studies in 
normal rats have shown that low dose MB enhances memory retention of:  (1) an 
inhibitory avoidance response (Martinez et al., 1978), (2) a baited holeboard 
pattern (Callaway et al., 2004), and (3) an extinguished conditioned response 
(Gonzalez-Lima and Bruchey, 2004).  However, these previous studies could 
also be explained by nonspecific drug effects on motor activity or feeding 
behavior rather than memory effects. 
The present results demonstrated that 1–10 mg/kg doses of MB improved 
memory retention without disrupting general activity, anxiety, or sweet-seeking 
feeding behavior in rats.  The 4 mg/kg dose was specifically selected for testing 
because humans have taken 300 mg/day of MB for one year without significant 
side effects (Naylor et al., 1986).  This dose corresponds to 4.3 mg/kg for a 70 kg 
person. 
For the memory tests, rats were injected with 1–10 mg/kg MB after the 
end of the training session in day 1 and tested for improved memory retention 24 
h later.  Post-training MB administration was chosen in order to target the 
processes of memory consolidation and to enhance brain metabolic processes 
underlying the retention of the memory when tested 24 h later (McGaugh, 2000; 
Cooke et al., 2004).  Therefore, MB could not interfere with acquisition learning 
because it was administered after training. 
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3.5.1  Behavioral Effects of MB 
Low dose MB significantly improved memory in the object recognition 
task.  Although all groups explored the novel object longer than the familiar one, 
the difference was significant only in the rats injected with 4–10 mg/kg MB.  In 
the open field test, the lower 1–4 mg/kg MB doses generally improved the 
habituation effect.  The only dose to improve memory in both tasks was 4 mg/kg 
MB.  The higher 10 mg/kg MB dose produced increased exploration in the open 
field chamber and high variance in the object recognition test.  This suggests that 
MB shows the same bell-shaped dose effects on memory as other cognitive 
enhancers (Flood et al., 1981; Baxter et al., 1994). 
One alternative interpretation of the memory experiments is that MB could 
simply modify locomotor activity, thereby creating a habituation or object 
recognition effect.  However, locomotor behavior during a 24 h session in the 
running wheel was not different in the 1–10 mg/kg MB groups as compared with 
the saline group.  This suggests that MB has a specific effect on memory which 
could not be explained by a nonspecific locomotor effect.  Furthermore, a 
nonspecific modification of locomotor behavior would not account for the longer 
amount of time spent exploring the novel object in the MB-treated groups. 
Another possibility is that low dose MB may be anxiolytic and thus 
stimulate exploratory behavior.  Anxiety in rats is associated with increased 
thigmotaxic behavior (more activity in the periphery of the chamber) and center 
avoidance (less crossings into the center of the chamber) (Treit and Fundytus, 
1988).  In our study, there were no differences in center crossings in the open 
field in rats given 1–10 mg/kg MB.  This implies that low dose MB does not affect 
anxiety-related behaviors.  In addition, Gonzalez-Lima and Bruchey (2004) found 
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no evidence of nonspecific effects on measures of exploration and anxiety in rats 
treated with one or five daily injections of 4 mg/kg MB.  Therefore, the effects 
following post-administration of 4 mg/kg MB on habituation and object recognition 
are the result of enhanced memory retention.  This improvement is consistent 
with a Pavlovian study showing that 4 mg/kg MB improved retention of extinction 
memory during the post-extinction phase (Gonzalez-Lima and Bruchey, 2004). 
3.5.2  Effects of MB on Brain Oxygen Consumption 
Oxidative metabolism examined in vitro with an optical oxygen sensor 
revealed a dose-dependent effect of MB.  Both 5 µM and 10 µM LMB 
significantly increased oxygen consumption.  The effect of 0.5 µM LMB did not 
reach statistical significance after Dunnett correction.  We previously 
demonstrated that 0.5 µM MB increased C.O. activity while 5 µM had no effect 
and 10 µM decreased activity (Callaway et al., 2004).  One important difference 
in the two methods employed is that the reduced form (LMB) was used in the 
oxygen recordings but the oxidized form (MB) was used in the C.O. activity 
measurements.  The reduced form is favored for entry into the cell (Merker et al., 
1997).  Because there were only a few seconds of incubation with MB or LMB in 
both protocols, the amount entering the cell in the C.O. activity measurements 
was probably lower than that applied in the oxygen probe protocol and therefore 
not directly comparable.  With a short incubation period, 5 µM MB may enter at a 
concentration closer to 0.5 µM LMB.  At these concentrations, no differences 
were found in either measurement. 
It is also possible that increasing the amount of MB changes its 
mechanism within the electron transport chain.  MB may directly reduce oxygen 
at higher concentrations (10 µM MB, 5 µM LMB) and prevent C.O. from donating 
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its electrons to oxygen, thereby inhibiting C.O. activity.  A direct action on oxygen 
would explain the decrease in the rate of cytochrome c oxidation with 10 µM MB 
and the increase in oxygen consumption observed with 5 µM LMB. 
Callaway et al. (2004) showed that C.O. activity increased 24 h after a 
single 1 mg/kg MB injection, but not after 1 or 2 h post-administration.  In the 
present experiment, 1 mg/kg MB increased oxygen utilization 24 h after in vivo 
administration.  Oxygen consumption was not different 1 or 2 h after MB 
treatment.  The results from the respiratory metabolism experiments agree with 
Visarius et al. (1997) who showed that 0.5–2 µM MB stimulates cellular 
respiration in rat liver.  Taken together, these studies indicate that improved brain 
energy metabolism is a mechanism whereby MB increases memory retention.   
Brain C.O. activity can be partially inhibited by chronic sodium azide 
administration (Cada et al., 1995; Berndt et al., 2001).  Systemic administration in 
rats causes memory deficits in the Morris water maze (Bennett et al., 1992) and 
the holeboard maze (Callaway et al., 2002).  When low dose MB was 
administered to rats treated with sodium azide, their impaired memory retention 
was normalized to levels comparable to control rats (Callaway et al., 2002).  The 
following study will determine whether 4 mg/kg MB can reverse spatial memory 
impairment caused by focal administration of sodium azide in the PCC. 
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Chapter 4:  Methylene Blue Prevents Memory Impairment in a 
Spatial Task Caused by PCC Hypometabolism 
 
4.1  ABSTRACT 
Hypometabolism in the posterior cingulate cortex (PCC) in patients with 
mild cognitive impairment is a major risk factor for developing Alzheimer’s 
disease.  In rats, PCC metabolic inhibition produces spatial memory deficits, 
oxidative damage, and neurodegeneration.  Methylene blue (MB) is a chemical 
compound that enhances memory, increases cytochrome oxidase (C.O.) activity 
and oxygen consumption, and has antioxidant properties.  This study tested the 
neuroprotective and memory-enhancing properties of MB in rats that received an 
injection of sodium azide, an inhibitor of C.O., directly in the PCC.  Sodium azide 
administration resulted in impaired spatial memory in a holeboard food-search 
task.  In addition, sodium azide-treated rats had significantly fewer correlations in 
C.O. activity between the PCC and other brain region as compared to the control 
rats.  Co-administration of 4 mg/kg MB prevented the memory impairment and 
maintained several of the significant brain interregional correlations that were 
found in the control group.  Specifically, correlations in C.O. activity between the 
PCC and hippocampal areas, and between the PCC and secondary motor 
cortex, were preserved.  Our results suggest that memory impairment associated 
with PCC hypometabolism can be prevented by interventions that strengthen the 
functional connectivity of the PCC or that optimize the metabolic function of 
regions that mediate spatial memory.   
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4.2  INTRODUCTION 
Patients with neurodegenerative disorders such as Parkinson’s, 
Huntington’s and Alzheimer’s disease (AD) commonly show impaired 
mitochondrial metabolism (Cassarino and Bennett, 1999; Beal, 2005; Petrozzi et 
al., 2007).  Selective hypometabolism in the posterior cingulate cortex (PCC) is a 
major risk factor in subjects with mild cognitive impairment to develop AD 
(Mosconi, 2005; Borroni et al., 2006).  In both peripheral and brain tissue from 
AD patients, there is a specific impairment in the activity of cytochrome oxidase 
(C.O.), the rate-limiting enzyme in the mitochondrial respiratory chain (Parker et 
al., 1994a; Parker et al., 1994b; Gonzalez-Lima and Cada, 1998; Cardoso et al., 
2004a).  However, hypometabolism in the brains of AD subjects is not 
widespread.  C.O. inhibition has been found in the PCC, an area of the brain 
involved in spatial memory (Valla et al., 2001).  However, the adjacent motor 
cortex was not affected.  A recent paper reported a significant decrease in C.O. 
activity in peripheral tissue from subjects with mild cognitive impairment (Valla et 
al., 2006a).  Therefore, C.O. inhibition may not only determine the progression to 
AD, but perhaps also determine the initiation to AD.   
 C.O. is the terminal enzyme in the mitochondrial electron transport chain.  
It catalyzes electron transport to oxygen while concurrently generating ATP 
(Gonzalez-Lima and Cada, 1998).  C.O. activity is tightly correlated with 
metabolic neural activation (Wong-Riley et al., 1998).  Experimental inhibition of 
C.O. activity with sodium azide causes memory impairments in animals.  For 
example, systemic treatment in rats causes memory deficits in spatial tests such 
as the Morris water maze, radial arm maze, and holeboard task (Bennett et al., 
1992; Bennett and Rose, 1992; Callaway et al., 2004).  Rats receiving focal 
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administration of sodium azide directly into the PCC have memory deficits in a 
holeboard task and impaired PCC metabolism (chapter 2).  C.O. inhibition leads 
to decreased oxygen consumption, ATP, and increased free radical formation 
(Brouillet et al., 1994; Swerdlow et al., 1997; chapter 2; Riha et al., 2005/chapter 
3).   
Drugs that reverse the effects of C.O. inhibition should improve memory 
retention in conditions involving impaired energy metabolism (Beal, 2005).  A 
candidate drug is methylene blue (MB), an auto-oxidizable compound that 
enhances electron flow in the mitochondrial respiratory chain (Scott and Hunter, 
1966) and displays antioxidant effects.  MB is an FDA-approved drug indicated 
for the treatment of methemoglobinemia (Wright et al., 1999).  MB possesses 
ideal pharmacokinetics for targeting neural tissue.  MB crosses the blood-brain-
barrier and accumulates in mitochondria (Merker et al., 1997; Visarius et al., 
1999; Peter et al., 2000) where it has a variety of cellular effects. 
MB restores inhibition of oxygen consumption caused by rotenone, an 
inhibitor of the first enzyme in the mitochondrial electron transport chain (Lindahl 
and Oberg, 1961; Zhang et al., 2006).  Moreover, MB prevents superoxide free 
radicals formed during reperfusion after ischemia (Kelner et al., 1988; Salaris et 
al., 1991).  MB also decreases free radical-induced lipid peroxidation (Salaris et 
al., 1991; Zhang et al., 2006).  Low concentrations (1-10 µM) of MB stimulate 
cellular respiration in rat liver (Visarius et al., 1997) and brain (Riha et al., 
2005/chapter 3).  Low dose MB increases brain C.O. activity in vitro and after 24 
hours administration in vivo in rats (Callaway et al., 2004; Gonzalez-Lima and 
Bruchey, 2004).  MB administration prevented cell death, decreased lipid 
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peroxidation, and increased oxygen consumption in mice displaying retinal 
degeneration caused by rotenone (Zhang et al., 2006) 
 The ability of low dose MB to increase C.O. activity and mitochondrial 
respiration can explain the reports of memory improvement in rats treated with 
MB.  In vivo, 1-4 mg/kg MB improves memory in an inhibitory avoidance task 
(Martinez et al., 1978), an appetitive food-search task (Callaway et al., 2004), 
and a discrimination task (Wrubel et al., 2007).  Other studies have demonstrated 
that 4 mg/kg MB improves memory retention in an object recognition test, 
habituation in a familiar environment, and extinction of fear in rats (Gonzalez-
Lima and Bruchey, 2004; Riha et al., 2005/chapter 3).  MB not only improves 
memory in normal rats, but also in rats with metabolic impairments.  For 
example, low dose MB prevented memory impairments in rats that were given 
system administration of sodium azide (Cada et al., 1995; Callaway et al., 2002).   
We hypothesized that low dose MB will prevent the memory deficits 
caused by isolated hypometabolism in the PCC.  Rats were trained in a baited 
holeboard food-search task.  After learning the task, two groups received bilateral 
injections of sodium azide directly in the PCC.  This was followed by systemic 
administration of 4 mg/kg MB or saline.  One day after surgery, the rats were 
tested in the holeboard chamber for memory retention of the previously-baited 
pattern.  In addition, locomotor activity was evaluated to determine if there were 
nonspecific effects from sodium azide (AZ) or sodium azide plus MB (AZ+MB) 
treatment that would confound holeboard performance.  Finally, histochemistry of 
C.O. activity determined if there are metabolic changes in the brain due to 
treatment.  It is well-established that low dose MB improves memory.  The 
current experiment will further evaluate MB as a memory-enhancing compound 
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and provide evidence as to the mechanism by which MB prevents memory 
deficits.   
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4.3  METHODS 
4.3.1  Subjects 
For the holeboard study, subjects were 30 adult male Sprague Dawley 
rats (Harlan, Houston, TX) weighing 219–255 g on the first day of training.  They 
were single-housed on a 12 h light-dark schedule and allowed to drink water ad 
libitum.  For motivational purposes, rats were placed on a food restriction 
protocol that ensured they did not weigh less than 85% of free-feeding rats of a 
similar age.  They were fed daily at the end of their light cycle.  Beginning five 
days before training, animals were weighed and handled daily for 5 min.  On 
each of the two days before habituation, two sucrose food pellets (45 mg, Noyes, 
Lancaster, NH) were placed in their home cage.  These sucrose pellets were the 
same reinforcers used for training in the holeboard chamber.  All procedures 
were approved by the institutional animal care and use committee (IACUC) at the 
University of Texas at Austin.  The experiments were conducted in a facility 
accredited by the Association for Assessment and Accreditation of Laboratory 
Animal Care (AAALAC) International. 
4.3.2  Behavioral Procedures 
4.3.2.1  Apparatus 
The holeboard and locomotor tests were conducted in automated open 
field chambers purchased from MED Associates (St. Albans, VT).  The testing 
environments were composed of clear Plexiglas sides 30.5 cm high and a white 
fiberglass floor (43.2 cm2).  Parallel arrays of infrared motion detectors (16 X 16, 
2.5 cm apart) detected nosepokes in the holeboard task and locomotor activity in 
the open field test.   
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For the holeboard task, a top floor was placed in the chamber 2 cm above 
a bottom insert.  The top holeboard floor was made of metal and contained 16 
holes (4 X 4, 3.2 cm2).  The outer holes were 8.6 cm from the wall and the rows 
were 4.5 cm apart.  The bottom insert contained a bottom tray, wire screen, and 
a top tray.  The bottom tray had 16 holes of the same dimensions as the top task 
floor.  Five inaccessible sucrose pellets were placed in each hole.  The top tray 
secured the wire screen over the bottom tray.  The underlying food pellets 
controlled for odor that may emanate from the baited holes.  Thus, an animal 
should not be able to successfully detect the baited holes based on odor cues.   
4.3.2.2  Habituation & Training 
Animals were run in cohorts of 4–5 rats, resulting in a total number of 6 
cohorts.  Cohorts were transported from their homeroom to the testing room in 
clear plastic cages placed on a metal cart.  Each subject was alternatively run 
until all rats in that cohort finished their daily trials.  The holeboard procedure was 
performed in a dimly-lit room (33 lux) with proximal spatial cues placed around 
the chamber. 
Animals were first exposed to the chamber during habituation.  One 
sucrose pellet was placed in each hole for the habituation trials.  Before each 
trial, the chamber and holes were cleaned with a mild detergent (Bio-Clean, 
Stanbio Laboratories, Boerne, TX).  The holeboard insert was rotated between 
trials to further mask odor cues.  Rats were placed in the northeast corner of the 
chamber.  A trial began when the subject initiated the first nosepoke, and lasted 
for 5 min or until all bait was consumed.  Habituation trials were continued until 
rats consumed at least 15 pellets in one trial.  This criterion was reached in 2 to 4 
trials.   
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Holeboard training began the day following habituation.  The rats were run 
in the same cohort as in their habituation trials.  Four holes were baited in a 
consistent pattern for all subjects throughout training (Figure 1).  A trial started as 
soon as the first hole was nosepoked and ended immediately after the last bait 






Figure 4.1 Schematic drawing of the holeboard task floor.  Filled circles 





Training continued for at least 8 days.  Training was stopped when 60% 
reference memory was attained or for a maximum of 14 days of training.  The 
intertrial interval was approximately 9 min.  Training scores were averaged each 
day.  Rats were matched into treatment groups based on their averaged 
reference memory scores across all days of training.  Surgery was performed the 
day after each rat’s last training trial.  Following a 24 h recovery period, subjects 
received an unbaited probe trial to test for memory retention.   
MED Associates software measured various parameters in the holeboard 
task:  baited holes visited, nonbaited holes visited, repeat visits to both types of 
holes, and latency to complete the trial.  Reference memory was calculated as 
the ratio of visits to baited holes divided by number of visits to all holes.  The 
holeboard probe tests were also videotaped.   
4.3.2.3  Locomotor Activity 
Locomotor activity was assessed in an open field chamber located in the 
same room as the holeboard task.  The overhead light used during the trials 
measured 560 lux.  Distal spatial cues were present in the room.  Subjects were 
individually transported to the room in opaque cages made of a different material 
than those used for the holeboard trials.  Experimenters carried the cages by 
hand using a different path than the one used during transport during holeboard 
training.  The above procedures were employed to make the context as different 
as possible from the holeboard task.  One 5 min trial was conducted on post-
training days 5–7.  Following the unbaited probe trial, animals were brought back 
to their home room.  The behavior room was prepared for locomotor testing and 
animals were run in the chamber for a second 5 min trial.  The open field 
chamber was cleaned between trials with Betadine (Purdue Pharma, Stamford, 
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CT).  Med Associates software calculated ambulatory time, stereotypic time, and 
vertical counts.  Ambulatory time was defined as the number of seconds the rat 
was in ambulation.  Stereotypic time referred to the amount of time the rat broke 
the infrared beams without ambulating.  For example, scratching, grooming, and 
turning in a tight circle are counted as stereotypic behaviors.  Vertical counts 
were measured by beam breaks and indicated the number of times the animal 
reared. 
4.3.3  Surgery 
Rats were anesthetized by first placing them in a hostcage containing 97% 
breathing air and 3% isoflurane (Aerrane, Baxter Pharmaceutical Products, 
Deerfield, IL).  After the initial induction, the rat was moved to a heated surgical 
bed on a Stoelting stereotaxic frame, and secured in the flat skull position using 
ear bars and an incisor bar.  A nosecone positioned over the incisor bar was 
connected to a vaporizing machine that provided a steady flow of anesthesia (E-
Z Anesthesia, Euthanex Corp, Palmer, PA).  The subjects were continuously 
monitored for anesthesia state and the percentage of isoflurane was adjusted if 
necessary.   
The head was shaved and disinfected with Nolvasan (Wyeth, Madison, 
NJ).  Lacrilube (Allergan, Irvine, CA) was applied on the eyes to prevent drying.  
One injection of an NSAID was given intramuscularly to alleviate pain (Rimadyl, 5 
mg/kg, Pfizer).  A small mid-sagittal incision was made on top of the head and 
was kept open with a retractor.  The periosteum was removed by scraping with 
cotton swabs.  Two small bilateral holes (0.8 mm2) were drilled over the PCC on 
each side of the midline suture.  The rats in the AZ and AZ+MB groups were 
injected with 3 M sodium azide dissolved in phosphate buffer (pH 7.4).  This 
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concentration was previously determined to be effective at impairing spatial 
memory in the holeboard and energy metabolism (Brouillet et al., 1994; Chapter 
2).  Four bilateral injections were made in the following atlas coordinates (from 
Bregma, in mm):  A/P -2.8 to -3.3; M/L ±0.2 to 0.4; D/V -1.2 to -1.3, alternating 
left and right sides (Paxinos and Watson, 1997).  A flowmeter delivered each 
injection at a rate of 0.05 µL/min for 10 min.  After each infusion, the needle was 
kept in place for a few minutes and slowly removed.   
After the injections, the skin was sutured with wound clips (Reflex, 
CellPoint Scientific, Gaithersburg, MD) and Neosporin was applied to the wound.  
Subjects in the AZ+MB group (n = 9) were injected intraperitoneally with 4 mg/kg 
MB (Faulding Pharmaceuticals, Paramus, NJ) at the end of surgery.  The control 
group (n = 10) and AZ group (n = 10) received an equivalent volume of 0.9% 
saline intraperitoneally.  After recovering from surgery (5–10 minutes), the rats 
were returned to their home cage and monitored to ensure full recovery.  The 
control rats received the same surgical treatment and spent an equivalent 
amount of time under anesthesia, but they did not receive a craniotomy.  
4.3.4  Brain Procedures 
4.3.4.1  Brain Processing: 
After the second assessment of locomotor activity, the rats were killed by 
decapitation.  Their brains were quickly extracted, frozen in isopentane, and 
stored in an ultra-low freezer at -40°C.  The brains were cut in 40 µm coronal 
sections in a -17°C cryostat and collected onto glass slides.  Two adjacent series 
were created.  One was stained for C.O. activity for quantitative histochemical 
analysis and the other was stained with cresyl violet for cell counting.   The slides 
were kept in an ultra-low freezer at -40°C until processed.   
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4.3.4.2  Cytochrome Oxidase Histochemistry 
The brains were stained in batches for C.O. histochemistry.  Each batch 
included two standard slides that contained tissue sections of varying thickness 
(10, 20, 40, 60, and 80 µm).  The standards were cut from frozen rat brain 
homogenate with known C.O. activity that was determined in a previous 
experiment.  The details of quantitative C.O. histochemistry have been published 
(Gonzalez-Lima and Jones, 1994; Gonzalez-Lima and Cada, 1998).   
All chemicals were purchased from Sigma.  Fresh-frozen brain sections 
were immediately placed in a cold bath of 0.5% glutaraldehyde and 9% sucrose 
phosphate buffer solution (PBS, 0.1 M, pH 7.4) for 5 min.  Next, they were 
immersed in three changes of sucrose PBS for 5 min each.  These washes were 
at graded temperatures in order to slowly increase the temperature of the tissue.  
Then, they were placed for 10 min in a preincubation intensification Tris buffer 
containing 774 mL of 0.1 N HCl, 10 mL dimethylsulfoxide, 12 g trizma base, 200 
g sucrose, and 0.55 g cobalt chloride in 1226 mL double-distilled water.  After a 
rinse in PBS without sucrose, the tissue was stained for C.O. activity in an 
oxygen-saturated solution at 37°C for 60 min.  The incubation solution contained 
0.35 g 3,3’-diaminobenzidine tetrahydrochloride, 52.5 mg cytochrome c (from 
horse heart), 14 mg catalase, 35 g sucrose, and 1.75 mL DMSO in 700 mL PBS.  
The incubation was followed by 30 min in a bath of 4% formalin in sucrose PBS 
in order to stop the reaction and fix the tissue.  Subsequently, the slides were 
slowly dehydrated by passing through increasing concentrations of ethanol 
washes (30, 50, 70, 95, 95, 100 and 100%) for 5 min each.  Finally, the tissue 
was cleared in xylene (3 times, 5 min each) and coverslipped with Permount. 
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4.3.4.3  Cytochrome Oxidase Image Analysis: 
The C.O. content in nerve tissue is closely correlated with the optical 
density (O.D.) of histochemically-stained sections (Hevner and Wong-Riley, 
1989).  O.D. of the stained brain standards and the brain sections were 
measured using a computer-assisted image analysis system consisting of a DC-
powered lightbox, a CCD camera (Javelin Electronics, Torrance, CA), a Targa 
M8 image capture board, and JAVA imaging software (Jandel Scientific, Corte 
Madera, CA).  Java calibrated gray level values from a Kodak step tablet into 
known O.D. and subsequent measurements were recorded as O.D. (Gonzalez-
Lima and Cada, 1998). 
For each section thickness of one brain standard per batch, ten O.D. 
measurements were averaged and the mean values were used to obtain a 
regression equation.  Using this equation, O.D. values were converted to units of 
C.O. activity (µmol/min/g tissue).  Regression equations calculated from standard 
O.D. values confirmed the linearity of the C.O. histochemical reaction (r2 > .94).   
For each subject, the O.D. of each region of interest was measured 
bilaterally in three adjacent sections.  The field of view of each sample area was 
approximately 0.75 X 1.0 cm.  The median values for each region per subject 
were averaged to obtain the group average.  PCC activity in the dorsal and 
ventral aspects were analyzed throughout the entire rostral to caudal extent (-1.8 
to -5.3 mm from Bregma).  In addition, we also analyzed brain regions that 
connect to the PCC.   
The PCC is one of the regions included in the Papez circuit, which has 
been proposed to mediate emotion as well as processes of learning and memory 
(Papez, 1937; Vertes et al., 2001).  Therefore, we also measured activity in 
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regions of the Papez circuit.  These include:  the cingulate, entorhinal, and 
perirhinal cortices, hippocampus proper, subiculum, mammillary bodies, and 
anterior thalamic nuclei.  A brain atlas was used to delineate brain structures 
(Paxinos and Watson, 1997). 
4.3.4.4  Nissl Staining 
To determine if either AZ or AZ+MB treatment resulted in a change in the 
number of neuronal or glial cells, the second series of brain sections was stained 
with cresyl violet and used for cell count measurements in the PCC.  For each 
subject, the alternate slide to the one showing the least C.O. activity in the PCC 
was chosen for Nissl staining.  The procedure began with placing fresh-frozen 
tissue in a series of baths for 2.5 min each:  95% ethanol, 70% ethanol, double-
distilled water, and sodium acetate buffer (0.05 M, pH 4).  Next, the tissue was 
stained with 0.1% cresyl violet in sodium acetate buffer for 4 min at 45°C.  Slides 
were then placed in alternating series of 70% and 95% ethanol baths (5 min 
each) until visualization was optimal.  This was followed by dehydration in 
ethanol (95, 100, and 100%, 5 min each).  Finally, slides were cleared in xylene 
and coverslipped with Permount. 
4.3.4.5  Posterior Cingulate Cortex Cell Count 
Neuronal and glial cell counts were measured using a Labophot-2 
binocular bright field microscope (Nikon Corporation, Tokyo, Japan) connected to 
a DVC-340 scan camera, DVCView 3.3 imaging software (DVC Company, 
Austin, TX), a Microcode II digital readout (Boeckeler Instruments, Inc., Tucson, 
AZ), and a PC computer.  An unbiased optical disector stereological method 
(Harding et al., 1994) was used to estimate cell density (cells/volume) in the PCC 
in Nissl-stained sections from control (n = 6), AZ (n = 6), and AZ+MB (n = 6) 
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groups.  Cell density was estimated in three different PCC regions: 1) layers II/III 
of the dorsal PCC, 2) layers V/VI of the dorsal PCC, and 3) layers III/IV of the 
ventral PCC.  Cells were differentiated based on morphological criteria for brain 
cells.  Neurons were identified by large ellipsoidal/pyramidal cell body, low 
nucleus/cytoplasm ratio, heterochromatic nucleus, and visible nucleolus.  Glia 
were distinguished as cells with a small cell body, high nucleus/cytoplasm size 
ratio, and hyperchromatic nucleus.   
Cells were identified with a 50X oil immersion objective throughout the 
thickness of a section and were counted when they first came into focus within 
an unbiased counting frame (Harding et al., 1994).  Cells on the surface of the 
section were excluded from analysis.  For each PCC region, cells were counted 
from each of six sections per subject within a randomly chosen hemisphere.  Cell 
density was defined as Nvcells = ΣQ-/Σv(frame), where ΣQ- is the sum of cell counts 
per sample and Σv(frame) is the area of the unbiased counting frame (0.0396 mm2, 
adjusted for 140X magnification) multiplied by the length of the analyzed region 
(d).  The length was calculated as d = (No. of sections – 1) x No. of section series 
x section thickness.  Cell counts were measured by an experimenter blind to the 
treatments. 
4.3.5  Statistical Methods 
Reference memory scores were used to evaluate group differences in the 
holeboard task.  Scores were calculated as the ratio of total visits to baited holes 
divided by the total number of visits to all holes.  A repeated-measures analysis 
of variance (ANOVA) evaluated learning in the holeboard for the first eight days 
of training.  ANOVA compared group differences throughout training days 9–14 
and compared various measures in the probe test.  Reference memory in the 
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probe test was examined by ANOVA followed by planned comparisons.  
Repeated-measures ANOVA (day X group) was used to assess locomotor 
activity in the open field.  All significant group differences were further explored 
with Bonferroni-corrected comparisons.   
C.O. activity and cell counts between the three experimental groups were 
evaluated using ANOVA followed by tests for simple effects for each region of 
interest.  Within-group Pearson product moment correlations were computed to 
analyze the relationship in C.O. activity between the PCC and other brain regions 
(Nair and Gonzalez-Lima, 1999).  For all tests an alpha level of .05 (two-tailed) 
was the criteria of statistical significance.  All tests were performed using SPSS 
11.5 software (SPSS, Inc., Chicago, IL). 
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4.4  RESULTS 
4.4.1  Behavioral Analysis 
4.4.1.1  Holeboard Performance 
One rat failed to reach the criterion during habituation trials and was 
excluded from the study.  During the first eight days of training, all rats learned 
the holeboard pattern (Figure 2, F(7, 182) = 20.99, p < .001).  After day 8 of 
training, there were different numbers of subjects per group per day.  
Consequently, group scores across days 9–14 were averaged and evaluated 
with ANOVA.  There were no group differences in holeboard training within the 
first 8 days (F(2, 26) = 0.266) or in the remaining 9-14 days of training (F(2, 24) = 
2.95).  In addition, there were no group differences in reference memory for the 
last day of training or in the maximum training score. 
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Figure 4.2 Learning curves in the holeboard task before treatment.  Sample 
sizes are noted in parenthesis beneath each daily average. 
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There was a significant group difference in reference memory in the 
holeboard task (F(2, 26) = 6.78, p = .004; Figure 3).  The AZ group had 16% worse 
reference memory than the control group (Bonferroni p = .092, ns).  Mean ratios 
± S.E.M. of the AZ and control groups were 0.255 ± 0.018 and 0.304 ± 0.014, 
respectively.  The effect size of sodium azide was .97.  In addition, the AZ+MB 
group showed significantly better memory for the baited pattern (0.336 ± 0.015) 
as compared to the AZ group (Bonferroni p = .004).  Furthermore, AZ+MB-
treated rats showed similar reference memory as control rats.  The AZ group also 
showed the largest difference from their training average.  They showed a 37% 
reduction in reference memory as compared to the control group (27%) or the 
AZ+MB group (20%). 
Planned comparisons using Student’s t test revealed that the AZ-treated 
rats had significantly worse memory than rats in the control group (t(18) = -2.197, 
p = .041) and AZ+MB-treated group (t(17) = -3.472, p = .003).  However, there 
was not a significant mean difference between the AZ+MB-treated rats and the 
control rats (t(17) = 1.557, p = .138). 
There were no significant mean group differences in the probe test for the 
following measures:  the number of initial or repeated nosepokes into previously-
baited holes or previously-nonbaited holes; total entries into previously-baited or 
previously-nonbaited; or total entries.  The time to complete the probe test was 
not different between groups. 
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Figure 4.3 Mean ± S.E.M. of reference memory before (training) and after 
PCC hypometabolic induction (probe).  *significantly different from control and 







































4.4.1.2  Locomotor Activity 
There was a significant group effect for ambulatory time in the open field 
chamber (F(2, 26) = 3.66, p = .04).  However, post-hoc analysis did not reveal 
differences between any of the groups.  Examining the scores in Table 1 
suggests that the significant result in the omnibus test is due to the higher 
baseline activity in AZ-treated rats (both before and after administration).  All 
groups significantly decreased the amount of time performing stereotypic 
behaviors in the second trial, as compared to the first trial (F(1, 26) = 63.89, p < 
.001).  There was not a significant effect of drug treatment for stereotypic time or 






Table 4.1 Locomotor activity in the open field chamber before (Pre) and after 
(Post) drug treatment. 
    CONTROL           AZ       AZ + MB
MEASURE Pre Post (n) Pre Post (n) Pre Post (n)
      ambulatory time (s) 35 ± 3 32 ± 2 (10) 41 ± 2 43 ± 4 (10) 36 ± 2 32 ± 4 (9)
      stereotypic time (s) 82 ± 3 71 ± 3 (10) 79 ± 2 68 ± 3 (10) 83 ± 2 72 ± 2 (9)




4.4.2  Brain Findings 
4.4.2.1  Cytochrome Oxidase Histochemistry 
C.O. activity was quantified in the PCC, as well as in brain regions that 
have anatomical connections with the PCC or are included in the Papez circuit.  
The PCC was the only region that showed a mean group difference in C.O. 
activity (Table 2, F(2, 26) = 14.82, p < .001).  Both the AZ and AZ+MB groups were 
significantly different from the saline group (Bonferroni-corrected p < .01).  Rats 
treated with sodium azide showed a 17% decrease of C.O. activity in the PCC as 
compared to control rats, while the AZ+MB group had a 28% decrease.  Co-
administration of MB did not prevent the decrease in C.O. activity caused by 
sodium azide; PCC activity in the AZ+MB rats was similar to that in AZ rats 
(Figure 5).  Detailed analysis within the PCC revealed group differences in both 
the dorsal PCC and ventral PCC aspects (dorsal:  F(2, 26) = 16.73, p < .001 and 
ventral:  F(2, 26) = 12.55, p < .001).  Post-hoc analysis showed that while both AZ- 
and AZ+MB-treated rats were not different from each other, both had significantly 
less C.O. activity within the dorsal PCC area than the control rats (p < .001).  
Within the ventral PCC area of the PCC, the AZ+MB-treated rats had lower 
activity than both control rats and AZ-treated rats (p < .001 and p = .018, 
respectively).  The AZ-treated rats were not significantly different from the control 
animals in the ventral PCC. 
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Table 4.2 Mean ± S.E.M. of C.O. activity (µmoles/min/g tissue) in control rats 
and in rats injected with sodium azide in the PCC with (AZ+MB) or without MB 
treatment (AZ). 
AREA OF INTEREST CONTROL AZ AZ + MB
abbreviation Bregma level (mm) Mean ± SEM (n) Mean ± SEM (n) Mean ± SEM (n)
CINGULATE REGIONS
      posterior cingulate PCC 299 ± 7 (10) 249 ± 11 (10) * 215 ± 14 (9) *
          dorsal PCC RSA -1.80 to -5.30 285 ± 8 (10) 208 ± 14 (10) * 188 ± 15 (9) *
          ventral PCC RSG -1.80 to -5.30 313 ± 6 (10) 284 ± 8 (10) 242 ± 15 (9) * †
      anterior cingulate ACC  1.60 to -1.40 304 ± 5 (10) 297 ± 4 (10) 292 ± 5 (9)
      cingulum bundle cb -1.80 to -5.30 6 ± 5 (10) -6 ± 4 (10) -6 ± 3 (9)
THALAMIC REGIONS
      anterior dorsal AD -1.80 555 ± 35 (10) 542 ± 45 (10) 540 ± 30 (9)
      anterior ventral AV -1.80 343 ± 20 (10) 362 ± 21 (9) 335 ± 25 (9)
      anterior medial AM -1.80 239 ± 7 (9) 244 ± 10 (9) 234 ± 7 (9)
      reticular Rt -1.80 249 ± 7 (10) 267 ± 7 (10) 258 ± 7 (9)
      rhomboid/reuniens Rh/Re -1.80 240 ± 7 (10) 259 ± 8 (10) 244 ± 9 (9)
      lateral dorsal LD -2.30 319 ± 8 (10) 325 ± 11 (10) 315 ± 5 (9)
HIPPOCAMPAL FORMATION
anterior/dorsal
      CA1 CA1d -3.80 243 ± 6 (10) 244 ± 9 (10) 231 ± 8 (9)
      CA3 CA3d -3.80 241 ± 7 (10) 246 ± 6 (10) 242 ± 8 (9)
      dentate gyrus DGd -3.80 323 ± 8 (10) 327 ± 4 (10) 321 ± 3 (9)
posterior/ventral
      CA1 CA1v -5.30 198 ± 10 (10) 210 ± 7 (10) 215 ± 9 (9)
      CA3 CA3v -5.30 238 ± 8 (9) 248 ± 7 (10) 251 ± 8 (9)
      dentate gyrus DGv -5.30 192 ± 7 (10) 202 ± 7 (10) 210 ± 7 (9)
      subiculum SUB -5.30 188 ± 11 (10) 197 ± 9 (10) 189 ± 13 (9)
      mammillary bodies MB -4.80 296 ± 11 (7) 296 ± 8 (8) 316 ± 18 (7)
      entorhinal Ent -4.80 165 ± 8 (9) 179 ± 8 (10) 179 ± 7 (9)
      perirhinal PRh -4.80 170 ± 8 (10) 183 ± 6 (10) 188 ± 9 (9)
OTHER
secondary motor cortex M2 -0.26 268 ± 6 (10) 258 ± 2 (10) 270 ± 8 (9)
secondary visual cortex
      medial area V2M -5.30 251 ± 13 (10) 207 ± 12 (8) 240 ± 11 (9)
      lateral area V2L -5.30 249 ± 14 (10) 244 ± 10 (9) 261 ± 10 (9)
caudate putamen CPu -1.80 209 ± 8 (10) 198 ± 9 (10) 215 ± 9 (9)
zona incerta ZI -3.80 283 ± 8 (10) 293 ± 7 (10) 269 ± 8 (9)
periaqueductal gray PAG -5.30 224 ± 8 (9) 231 ± 7 (10) 223 ± 5 (9)
raphe nuclei RLi -5.30 168 ± 8 (6) 172 ± 15 (9) 130 ± 24 (7)
*signficantly different from control (p < .01 )
†signficantly different from AZ (p < .05 )  
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Figure 4.4 Representative sections of C.O.-stained brains around Bregma -
2.80 mm one day after treatment.   
A.  Control 
 
2.  AZ group 
 
3.  AZ+MB group 
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4.4.2.2  PCC-Interregional Correlations 
The significant values obtained from the correlational analysis of brain 
activity were positive in all three groups (Table 3).  Correlational analysis of brain 
C.O. activity between the PCC and other brain regions showed 12 significant 
correlations in the control group.  Sodium azide administration in the PCC 
decreased the total number of correlations.  There were seven and five 
significant correlations in the AZ and AZ+MB groups, respectively.   
Generally, AZ-treated rats showed significant positive correlations that 
were not found in the control group or in the AZ+MB group (Figure 5).  For 
example, the control group showed that brain activity in the PCC was correlated 
with the thalamic nuclei, anterior hippocampus proper, anterior cingulate cortex, 
and secondary visual cortices.  However, the AZ group showed positive 
correlations between the PCC and the perirhinal, entorhinal and secondary motor 
cortices.  In contrast, MB co-administration with sodium azide maintained some 
of the significant correlations found in the control group; specifically, those in the 
anterior hippocampus proper and V2M.  Maintaining these correlations may 
underlie the preservation in memory observed in sodium azide-treated rats that 
also received MB.  
Another interesting finding is that the AZ+MB-treated rats showed different 
correlations between the PCC and connecting brain regions as compared to the 
AZ-treated rats (Figure 5).  The largest effects were in the following areas:  RLi, 
M2, ATN, Rhinal Ctx, CPu, and ZI.  In addition, several of the correlations in the 
AZ+MB group were very different from the control group.  This suggests that the 
AZ+MB-treated rats were using a different, but equally efficient, strategy for 
memory retrieval. 
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Table 4.3 Significant Pearson correlation coefficients (r) of C.O. activity 
between the PCC and other brain regions.  Abbreviations are defined in Table 2. 
 
PCC-Interregional Correlations
      CONTROL              AZ           AZ+MB
AD -0.32 0.71 * -0.21
AM 0.67 * 0.19 0.45
Rt 0.72 * -0.13 -.001
Rh/Re 0.68 * 0.24 0.46
LD 0.91 * 0.58 0.18
DGd 0.75 * 0.10 0.70 *
Ca1d 0.64 * 0.25 0.77 *
ZI 0.81 * 0.13 0.85 *
PRh 0.37 0.79 * 0.07
Ent 0.30 0.93 * 0.29
DGv 0.38 0.67 * 0.17
Ca1v 0.78 * 0.65 * 0.44
Ca3v 0.33 0.79 * 0.26
Rli 0.08 0.16 0.78 *
V2M 0.83 * 0.53 0.88 *
V2L 0.87 * 0.61 0.55
ACC 0.76 * 0.46 0.45
M2 0.56 0.68 * 0.01
CPu 0.66 * 0.54 0.14
*significantly different from zero (p < .05)
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Figure 4.5 Functional coupling of the PCC as observed with pairwise 
correlations.  Arrow width is proportional to the magnitude of the Pearson 
correlation.  Positive correlations are shown as solid arrows and negative 
correlations are represented as segmented arrows.  ATN = AV + AD + AM.  
Rhinal Ctx = Ent + PRh.  Abbreviations are defined in Table 2.  *significantly 
different from zero, p < .05. 
 
A.  Control group 
 
B.  AZ group 
 
C.  AZ+MB group 
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4.4.2.3  PCC Cell Count 
Sodium azide treatment resulted in significantly fewer neurons and 
increased glia in all regions (Bonferroni p < .05).  Neuronal loss was the greatest 
in the superficial region of the dorsal PCC (Figure 6).  The AZ group had a 76% 
decrease in neurons as compared to the control group (F(2, 15) = 12.93, 
Bonferroni-corrected p = .001).  Thus, the decrease in C.O. activity in the PCC 
might be due, in part, to cell death.  The largest increase in glia was found in the 
deep region of the dorsal PCC.  In this region, sodium azide treatment increased 
the number of glia by 200% compared to control animals (F(2, 15) = 7.314, 
Bonferroni-corrected p = .021).  AZ+MB-treated rats also had significant 
differences in cell counts in all regions as compared to control rats.  Cell density 
decreases in the AZ+MB group were similar to those observed in the AZ group in 
all regions (p = 1.0).  This indicates that MB co-administration did not confer 
neuroprotection against sodium azide-mediated toxicity. 
 
 115 
Figure 4.6 Neuronal and glial cell densities in the PCC in control, AZ and 
AZ+MB groups.  *significantly different from control, p < .05. 
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4.5  DISCUSSION 
The present study demonstrated that a single systemic injection of 4 
mg/kg MB prevented the memory deficits that occurred from PCC 
hypometabolism.  MB likely increased the functional interactions between brain 
regions that mediate spatial memory retention.  PCC hypometabolism was 
induced by a local injection of sodium azide, a mitochondrial inhibitor of C.O. 
activity, in the PCC.  The AZ-treated rats had lower reference memory scores 
than both control and AZ+MB-treated rats.  However, the AZ+MB-treated group 
had reference memory scores similar to those of control subjects.    
Rats were treated with sodium azide after they learned the baited 
holeboard pattern.  Thus, the memory retention deficits were not confounded by 
hypometabolism during the learning phase.  In addition, neither AZ- nor AZ+MB-
treated rats were different from control rats in exploratory activity in an open field 
chamber.  Finally, there were no significant group differences in the total number 
of nosepokes or in latency to complete the task.  Therefore, memory impairment 
in the AZ group was due to the inability to retrieve the previously-baited pattern, 
and not due to motor deficits.  Similarly, the memory-enhancing effect of MB 
cannot be explained by a change in exploratory activity.  
The systemic effects of MB were not mediated by an increase in neural 
metabolic activity in the PCC or in other brain regions.  This is supported by the 
fact that PCC C.O. activity levels in the AZ+MB group were lower than the control 
group and similar to the AZ-treated group.  Furthermore, there were no between-
group differences in C.O. activity in other measured brain regions.  This also 
suggests that sodium azide is a strong inhibitor of C.O. and that MB did not 
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displace the binding of sodium azide to C.O., which might prevent the memory 
impairment due to sodium azide.   
The MB effect on reference memory does not seem to be mediated by a 
direct neuroprotective effect against sodium azide toxicity.  Neural cell density in 
the PCC was significantly decreased in both AZ- and AZ+MB-treated animals as 
compared to control animals.  Moreover, this decrease was accompanied by 
massive gliosis in both treatment groups.  Therefore, the overall decrease in 
neuronal density, even in the presence of MB, suggests that prevention of cell 
death in the PCC was not a mechanism mediating the effects of MB on memory. 
A plausible explanation for the memory-enhancing effect of MB may be 
through its metabolic-enhancing effects on regions functionally connected with 
the PCC or other brain regions involved in reference memory.  This possibility is 
supported by the correlations between the PCC and connecting brain regions.  
The AZ+MB group showed correlations that were quite different from the control 
and AZ-treated groups.  This suggests that an alternative network, such as one 
that does not require the PCC, was recruited in the AZ+MB-treated rats.  
Furthermore, the data showed that MB preserved some of the significant 
correlations observed in the control group.  In the control group, C.O. activity in 
the PCC was positively correlated with the activity in the thalamic nuclei, 
hippocampus proper, anterior cingulate cortex, and secondary visual cortices.  
The anterior thalamus, hippocampus proper, and cingulate cortices are included 
in the Papez circuit, a proposed pathway underlying learning and memory 
(Papez, 1937; Vertes et al., 2001).  Treatment with sodium azide and MB 
changed these functional interactions.  Sodium azide decreased the number of 
significant correlations as well as created significant correlations not found in the 
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control group.  Conversely, co-administration of MB maintained some of the 
significant correlations observed in the control group.  Specifically, the 
correlations were between the PCC and the hippocampus, and the PCC and 
secondary visual cortex.   
The only new correlation in the AZ+MB group was a significantly positive 
correlation between the PCC and the raphe nucleus.  Both of these regions had 
lower C.O. activity than the control and AZ groups.  Serotonin generally inhibits 
cortical activity.  By inhibiting monamine oxidase activity in the raphe nucleus, 
MB may enhance the serotonin-inhibiting effects in the PCC and thereby, 
indirectly inhibit C.O. activity in the PCC (Lerch et al., 2006).   
MB administration increases oxygen consumption both in vitro and in vivo 
(Lindahl and Oberg, 1961; Riha et al., 2005; Zhang et al., 2006).  Previous 
studies found that MB improved oxygen consumption when complex I of the 
mitochondrial respiratory chain was inhibited (Lindahl and Oberg, 1961; Zhang et 
al., 2006).  It is possible that MB has the same effect of increasing oxygen 
consumption when C.O. is inhibited.  We did not measure oxygen consumption in 
the PCC after MB treatment in this study.  MB may have a greater affinity for 
transferring electrons directly to oxygen in cellular systems with exogenous 
mitochondrial inhibitors.  Future studies will attempt to resolve the mechanism of 
action of MB in relation to memory improvement during metabolic inhibition.  A 
drug that increases cellular respiration will likely improve learning and memory in 
patients with conditions characterized by metabolic defects such as AD. 
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Chapter 5:  General Discussion 
 
There is a need to create animal models that exhibit the early 
pathophysiology of AD.  Animals that mimic the abnormalities observed in early 
stage AD will help us to understand the mechanisms underlying progressive 
neurodegeneration.   Drugs approved for AD have only a modest effect on 
memory, so an appropriate model will allow us to test novel and effective 
therapeutic drugs. 
Human functional imaging in AD patients reveals that the first brain region 
to show decreased metabolism is the PCC (Minoshima et al., 1997; Johnson et 
al., 2006).  PCC hypometabolism is also a predictor for patients with MCI to later 
develop AD (Mosconi, 2005).  In particular, mitochondrial cytochrome oxidase 
(C.O.) activity is decreased within the PCC in AD (Valla et al., 2001).  C.O. 
activity is an indicator of neuronal activity and therefore, C.O. inhibition may 
contribute to the decreased signals observed during functional neuroimaging of 
AD patients. 
Evidence from human and animal studies illustrates that the PCC 
contributes to a network supporting spatial orientation and memory (Cammalleri 
et al., 1996; Berthoz, 1997; Whishaw et al., 2001; Harker and Whishaw, 2002).  
Functional impairment in this region may underlie the spatial orientation and 
memory deficits reported in AD patients (de la Torre, 2000; Holroyd and 
Shepherd, 2001). 
Inhibition of brain C.O. activity and resulting learning and memory 
impairments can be modeled in rats.  Two-week administration of sodium azide 
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through a continuous-release osmotic pump at a dose of 1 mg/kg/hr partially 
inhibits C.O. activity (Bennett et al., 1992; Cada et al., 1995; Berndt et al., 2001).  
This degree of C.O. inhibition resulted in memory deficits in active avoidance and 
spatial tasks such as the Morris water maze, radial arm maze, and holeboard 
task (Bennett et al., 1992; Bennett and Rose, 1992; Bennett et al., 1996a; 
Callaway et al., 2002; Luques et al., 2007).  These behavioral studies did not 
analyze regional brain C.O. activity associated with these deficits.  Interestingly, 
the memory deficits in the holeboard task were reversed with methylene blue 
(MB) treatment (Callaway et al., 2002).  Administration of 1 mg/kg MB restored 
spatial memory retention impaired by systemic administration of sodium azide 
and was associated with an increase in C.O. activity (Callaway et al., 2002; 
Callaway et al., 2004).  
Systemic C.O. inhibition differentially affects regional brain metabolism; 
the decreases in C.O. activity ranged from 26–37% (Cada et al., 1995).  This is 
comparable to the 24–39% decrease in C.O. activity found in the PCC in AD 
brains (Valla et al., 2001).  Focal administration of sodium azide in the striatum 
decreases the concentration of several neurochemicals, including ATP (Brouillet 
et al., 1994).  However, the regional effects of focal administration of sodium 
azide on brain C.O. activity and behavior have not been examined.   
This dissertation addressed the hypothesis that isolated C.O. inhibition in 
the PCC impairs memory in a spatial task and that this deficit can be reversed by 
MB administration.  We tested spatial memory in rats after bilateral injections of 
sodium azide in the PCC.  The results confirm that inhibition of C.O. activity 
impairs spatial learning and memory.  Specifically, inhibition of PCC metabolism 
alone is sufficient to cause deficits in memory retention in a spatial holeboard 
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task.  This is not to say that the PCC is the only region responsible for spatial 
navigation.  Rather, these studies confirm that the PCC is an important 
component in a network that mediates spatial memory.  In addition, low dose MB 
prevented memory impairment caused by sodium azide.   
 
5.1  Summary of Findings 
5.1.1  Energy Hypometabolism in the PCC Causes Spatial Memory 
Impairment Associated with Oxidative Damage and Cell Loss 
The first experiment examined if hypometabolism in the PCC is sufficient 
to cause spatial memory impairment.  Rats were trained in a food retrieval task 
using a holeboard.  After they acquired the task, we injected sodium azide 
directly into the PCC and tested their memory 24 h later.  We found that inhibition 
of C.O. activity in the PCC significantly impaired memory of a previously-learned 
baited holeboard.  These results are consistent with extensive literature 
documenting PCC’s contribution to spatial memory processing (Sutherland et al., 
1988; Gabriel, 1993; Whishaw et al., 2001). 
After completion of the retraining phase five days after surgery, the brains 
were quickly removed and analyzed for C.O. activity.  Quantitative histochemistry 
confirmed regional metabolic inhibition and verified that the C.O. inhibition was 
limited to the PCC.  In addition, sodium azide produced significant increases in 
gliosis and neuronal loss in the PCC.  C.O. metabolic changes did not occur in 
regions that are anatomically connected to the PCC.  PCC-interregional 
correlations in control animals revealed that:  1) C.O. activity in the PCC was 
positively correlated with secondary visual areas and the hippocampal formation 
(DGv, CA1v, CA3v, SUB, PRh, Ent); and 2) PCC activity was positively 
correlated with the caudate putamen, an area that contains head-direction cells 
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(Taube, 1998).  These significant positive correlations were not present in 
animals with PCC hypometabolism.  In the sodium azide-treated group, there 
was only one negative correlation—between the PCC and CA3d.  Therefore, 
C.O. inhibition resulted in functional dissociation between the PCC and visual 
and hippocampal areas.  Such dissocation may have contributed to the spatial 
memory deficits observed in this group.  To our knowledge, this is the first study 
in rats to show that memory impairment caused by isolated energy 
hypometabolism in the PCC is associated with functional uncoupling between the 
PCC and other brain regions involved in spatial memory. 
During retraining, the sodium azide-treated rats performed at the same 
level as control rats.  It is plausible that the young adult rats in our study were 
using compensatory or competing learning processes during this training phase.  
In the holeboard task, response/procedural learning could also yield high 
reference memory (Whishaw et al., 2001).  Perhaps if the PCC was damaged, 
and allocentric processing disturbed, the alternate strategy could dominate.  
Desgranges et al. (2002) showed that limbic brain areas such as entorhinal and 
posterior cingulate cortices were associated with episodic memory in healthy 
controls and less severely-affected AD patients; while neocortical structures were 
more correlated with better recall in patients with severe AD.  These results 
suggest that although the entorhinal cortex and PCC are impaired early in AD, 
other brain regions compensate to process memory.  In our study, a similar 
phenomenon may have occurred during retraining in sodium azide-treated rats. 
 
5.1.2  Low Dose MB Enhances Memory and Improves Cellular Respiration 
The second study proposed that low dose MB can enhance memory and 
brain oxygen utilization without nonspecific effects on behavior and motivation.  
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We determined that rats treated with low dose MB improved memory retention 
without affecting locomotion, exploration, or motivation.  Our lab has previously 
conducted studies that suggest that low dose MB facilitates memory retention in 
rats by increasing brain C.O. activity (Callaway et al., 2004; Gonzalez-Lima and 
Bruchey, 2004; Wrubel et al., 2007). 
Our dose-response study determined the proper MB dose that facilitated 
memory without changing general behavioral activity.  Administration of 4 mg/kg 
MB improved memory in both tasks without changing nonspecific behaviors.  
Generally, the 1–10 mg/kg MB-treated rats did not differ from saline-treated rats 
in locomotor activity or motivation.  But, rats treated with higher doses of MB (50 
and 100 mg/kg) showed locomotor impairment and decreased motivation.  The 4 
mg/kg MB dose improved behavioral habituation in an open field chamber.  The 
4 mg/kg and 10 mg/kg MB doses improved object recognition, a task that is 
believed to test episodic memory in rats (Lebrun et al., 2000).  Rats injected with 
10 mg/kg MB dose showed increased exploration in the open field and high 
variance in the object recognition test.   
In the second study, we also determined that 1 mg/kg MB increased brain 
oxygen consumption 24 h after administration.  Our study is the first to show a 
direct increase of brain oxygen consumption following MB administration.  Our 
findings are consistent with the Callaway et al. (2004) study that showed an 
increase in C.O. activity 24 h after a single 1 mg/kg MB injection.  This dose of 
MB was previously shown to reverse memory impairment caused by chronic 
sodium azide treatment (Callaway et al., 2002).  Together, these studies 
demonstrate that low dose MB facilitates C.O. activity and increases oxygen 
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consumption.  Therefore, the memory-enhancing effects of MB may be due to 
increased brain oxygen consumption and C.O. activity.    
The dose-response effects of MB on C.O. activity in vitro revealed an 
inverted U-shaped dose-response curve between 0.5 µM and 10 µM, with the 
most effective concentration being 5 µM (Callaway et al., 2004).  Another study 
showed that 50 mg/kg MB given to mice impaired memory retention (Martinez et 
al., 1978).  The higher variance produced by 10 mg/kg MB in the object 
recognition test and the dose-response characteristics in the in vitro C.O. activity 
study indicates that MB has nootropic properties (Baxter et al., 1994) and may be 
beneficial for the treatment of AD. 
5.1.3  Low Dose MB Prevents Spatial Memory Impairment Caused by PCC 
Hypometabolism 
The third study tested the hypothesis that low dose MB reverses memory 
impairment caused by sodium azide administration in the PCC.  As determined in 
the previous study, the effective MB dose (4 mg/kg) was administered to rats with 
PCC hypometabolism and their spatial memory retention was tested using a 
holeboard task.  MB prevented the impairment in spatial memory that occurred 
from sodium azide.  Histochemistry determined the corresponding C.O. activity 
changes in the brain one day after injection.  As in the second study, the only 
region showing C.O. inhibition was the PCC.  MB did not prevent the metabolic 
impairment in the PCC caused by sodium azide administration. 
Consistent with our second study, sodium azide significantly increased 
glia and neuronal loss in both dorsal and ventral regions of the PCC.  This 
implies that C.O. inhibition was caused by enzyme loss rather than impaired 
catalytic activity.  Although MB prevented memory loss, it did not prevent cell 
loss, as determined in Nissl-stained brain tissue.  Neuronal and glial cell counts 
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in the PCC were the same between AZ-treated rats and AZ+MB-treated rats.  
One implication of these results is that the memory-enhancing effects of systemic 
MB administration were not mediated by prevention of sodium azide-induced 
neurotoxicity.  Zhang et al (2006) showed that rotenone-induced 
neurodegeneration in the retinal ganglion cell layer was prevented by the co-
administration of MB along with rotenone.  It is likely that local co-administration 
of MB in the PCC would confer neuroprotection in our model of focal PCC 
hypometabolism.   
MB treatment may have improved memory by mediating functional 
associations between brain regions, as evidenced by the PCC-interregional 
correlations.  Although there were only half as many significant correlations in the 
AZ+MB-treated group as compared to the control group, most of the correlations 
found in the AZ+MB group were identical to the correlations in the control group.  
In contrast, the AZ group only showed one significant correlation that was 
identical to the control group (between PCC and CA1v).  The common 
associations in the AZ+MB group and the control group included correlations 
between the PCC and dorsal hippocampus (DGd, CA1d), zona incerta, and 
secondary visual cortex.  In addition, although some of the significant correlations 
found in the control group were not significant in the AZ+MB group, their 
correlational value was higher than the same correlations in the AZ group.  
Horwitz (1987) noted that AD patients have fewer correlations in metabolic 
activity between cortical regions.  The change in PCC-interregional correlations 




Our studies confirm existing evidence that several structures are involved 
in spatial memory.  After a spatial memory task, metabolic activity in the PCC 
was significantly correlated with activity in the hippocampal formation, thalamic 
nuclei, and subicular, entorhinal, and perirhinal cortices.  An important novel 
finding were the significant correlations in metabolic activity in several areas of 
the Papez circuit, whose function has been proposed to mediate learning and 
memory (Valenstein et al., 1987; Holdstock et al., 2000; Harker and Whishaw, 
2002; van Groen et al., 2004).  PCC hypometabolism by focal injections of 
sodium azide eliminated several significant correlations between the PCC and 
other brain regions that were found in the control group.  The PCC-interregional 
correlations suggest that decreasing the functional relationships in the Papez 
network can impair memory.   
The PCC may be a vulnerable brain region.  It has a high baseline activity 
in healthy human subjects (Minoshima et al., 1997).  The PCC has extensive 
reciprocal connections with the anterior thalamic nuclei (Shibata, 1998).  
Approximately 70% of the anterior thalamic projections to the PCC are excitatory 
synapses (Gonzalo-Ruiz et al., 1997).  To fulfill a high energy demand, C.O. 
expression is upregulated (Wong-Riley et al., 1998), which makes the PCC 
vulnerable to other metabolic insults such as vascular problems or C.O. 
inhibition.  In rats, systemic administration of an NMDA antagonist produces 
region-specific neurotoxicity, with the PCC being the most affected region (Li et 
al., 2002).  Likewise, the PCC would be one of the first areas affected by C.O. 
inhibition that leads to compromised energy metabolism and eventually cell 
death.    
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5.2  Alternative Explanations   
1.  It is possible that the memory impairment observed in sodium azide-
treated rats was caused by diaschisis.  Diaschisis refers to functional changes in 
brain areas remote from the site of damage, but that is connected to it by 
neurons (Thirumala et al., 2002).  Diaschisis is one mechanism thought to 
underlie functional recovery in stroke recovery in humans (Seitz et al., 1999).  It 
is possible that the memory recovery in the sodium azide-treated subjects (study 
2) that occurred during retraining was a result of other brain regions 
compensating for the loss in function due to the lesion.   
However, if other brain regions compensated during the memory task, 
metabolic activity in that region would change to reflect such a situation.  Since 
brain function and metabolism are correlated, C.O. histochemistry would reveal if 
there were functional changes in other brain regions in the sodium azide-treated 
animals during retraining.  At the time examined, there were no differences in 
metabolic activity in other brain regions that might account for the memory 
impairment. 
2.  One explanation for the effects of MB on memory may be due to some 
cells in the PCC gaining function while others deteriorated.  For example, 
perhaps the spared neurons within the PCC increased plasticity and 
strengthened their connections to brain regions mediating spatial navigation.  
The analysis of C.O. histochemistry did not detail specific layers or cell types 
within the PCC.  Nissl-staining did not determine if there were differential effects 
between the AZ and AZ+MB groups.  However, the covariance analysis of 
metabolic activity between the PCC and other brain regions suggests a different 
possibility. 
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Covariance analysis of the PCC connections in the control group revealed 
high correlations between the PCC and connecting afferent and efferent regions.  
However, several of these correlations were greatly decreased in the AZ+MB-
treated rats.  Although the AZ+MB-treated rats showed significant PCC inhibition, 
they exhibited the same performance as control rats in the holeboard probe test.  
One possibility is that these two groups were using different memory strategies to 
perform the same retention test.  In the control group, the strategy was PCC-
dependent, but in the AZ+MB group, it was PCC-independent.  The idea of 
multiple memory systems acting in parallel or in an interactive manner is 
established in the literature (McIntyre et al., 2003).  Experimental studies in 
animals that confirm this theory show that lesioning one brain area facilitates task 
performance (Bussey et al., 1996).  Thus, in an intact animal, two strategies may 
compete or one may dominate during learning and memory.  However, when the 
tendency to use one of the strategies is removed, as with a lesion, the competing 
process proceeds.   
5.3  Improvements 
1.  AD is defined by chronic, progressive metabolic and memory 
impairment.  Our C.O. inhibition model did not produce memory impairment 
during the retraining stage.  In our studies, at the time of the probe test, there 
was a 17% decrease in C.O. activity in the PCC.  Chronic treatment with sodium 
azide results in learning and memory deficits that are associated with a 26–37% 
decrease in C.O. activity (Cada et al., 1995).  In our study, rats with PCC 
inhibition showed memory deficits one day after treatment but later recovered to 
the level of control rats.  It is possible that greater C.O. inhibition may cause 
progressive impairment.   
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2.  Because we were cautious not to spread sodium azide beyond the 
limits of the PCC, the anterior and dorsal regions showed more impairment than 
the posterior and ventral regions.  The dorsal and ventral regions of the PCC are 
distinct components that provide projections to different parts of the same area 
(van Groen and Wyss, 1992a; van Groen and Wyss, 2003; Shibata et al., 2004).  
These different projections may transmit different spatial information.  Partial 
lesions of the PCC produce a less severe impairment in spatial memory 
performance than complete lesions (Vann et al., 2003).  Thus, it is likely that 
greater impairment in the holeboard task would result from inhibiting these 
regions as well.  Future studies should attempt to inject in such a way as to 
impair the entire antero-posterior extent of the PCC.   
5.4  Future Directions 
1.  It is unclear if the sparing within the ventral PCC region was due to 
injection volume or, alternatively, differential C.O. vulnerability in the dorsal 
region.  Distinguishing among different neuronal populations could determine if 
some are more vulnerable to C.O. inhibition.  It is hypothesized that cells with 
high neuronal demand, and therefore high C.O. density, would show more 
inhibition from sodium azide treatment.  For example, pyramidal cells which 
receive a lot of glutamatergic innervation from anterior thalamic nuclei should be 
more affected than GABAergic interneurons.   
2.  To model the changes seen in Alzheimer’s patients, it would be 
interesting to combine another risk factor such as aging or vascular impairment 
(de la Torre et al., 2004) with the sodium azide-induced hypometabolism in order 
to induce greater energy failure.  This might better model chronic inhibition in AD 
patients.  For example, Bennett et al (Bennett et al., 1996a) found that 
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simultaneous administration of sodium azide and corticosterone impaired 
learning and memory in the water maze.  However, these doses did not impair 
learning when administered alone (Bennett et al., 1996b).  Corticosterone 
administration decreased glucose uptake and potentiated the energy impairment 
due to C.O. inhibition. 
5.5  A Novel Therapeutic Strategy 
AD is a devastating neurological disorder and the therapeutic options are 
limited.  Drugs that inhibit the breakdown of the neurotransmitter acetylcholine 
are the foundation of therapy.  Four of the five drugs on the market are 
acetylcholinesterase inhibitors; the fifth is memantine.  Although the majority of 
these drugs do not produce serious side effects, there is only a modest cognitive 
improvement, at best (Clegg et al., 2001; Delagarza, 2003; Loveman et al., 
2006).  In addition, the reports of their efficacy on global functioning, behavior, 
and mood are inconsistent (Clegg et al., 2001; Delagarza, 2003; Loveman et al., 
2006; Reisberg et al., 2006).    
It is not clear whether C.O. inhibition is the cause or the result of AD.  
However, it is apparent that C.O. inhibition occurs before the onset of cognitive 
decline (Blass et al., 2002).  Because C.O. activity and neuronal function are 
tightly coupled, any drug that enhances C.O. activity should lead to an increase 
in oxygen consumption and ATP synthesis.  One mechanism to alleviate the 
metabolic and possible behavioral consequences of C.O. inhibition is to increase 
mitochondrial respiration.  However, an increase in mitochondrial respiration may 
lead to increased free radical production.  MB is a compound that can both 
increase metabolism and decrease free radical production through its 
mechanisms as an electron transporter and as an antioxidant.   
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5.5.1  Mitochondria as a Therapeutic Target 
Mitochondria are a major source of free radicals and are responsible for 
activating apoptotic cell death.  Attempts to protect neurons by using antioxidants 
have been successful in animal studies of neuronal cell death (Kelso et al., 2001; 
Szeto, 2006).  MB is lipophilic and diffuses readily in the mitochondria with 
several beneficial mechanisms of action, such as decreasing free radicals, and 
increasing brain C.O. activity and oxygen consumption (Salaris et al., 1991; 
Callaway et al., 2004; Riha et al., 2005/chapter 3).  In vivo, MB increases 
mitochondrial long-chain fatty acid oxidation (Visarius et al., 1999).   Long-chain 
fatty acids provide structural components for various lipids and proteins, and are 
a high-energy source for OXPHOS.  Low dose MB (1-2 µM) also decreases 
amyloid aggregation and neurofibrillary tangle assembly in vitro (Wischik et al., 
1996; Taniguchi et al., 2005).  Thus, MB administration to AD patients may be 
highly beneficial:  it would not only increase brain metabolism and decrease free 
radical production, but would also decrease amyloid plaque formation and 
neurofibrillary tangles commonly observed in the late stages of AD.  Further 
research is necessary to determine the efficacy of MB on AD. 
MB provides neurons more metabolic energy to fuel energy demands that 
facilitate memory retention.  It is possible that MB may improve memory retention 
in humans with AD and other conditions that are characterized by metabolic 
energy deficiency, such as individuals with age-related memory impairment, 
stroke victims, and patients with vascular dementia (Valla et al., 2001; Aliev et 
al., 2003).  Memory impairment in AD is correlated with dysfunctional brain 
metabolism (de la Torre, 2004; Beal, 2005).  The ability to slow the disease 
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progression in patients with early-stage AD is foreseeable since MCI is 
recognized as a major risk factor for AD.   
Typical pharmacological treatments that improve memory modify specific 
neurotransmitters.  However, metabolic enhancers like MB that target 
mitochondria may improve overall brain energy production and memory retention 
without producing the side effects associated with modifying a particular 
neurotransmitter system.  MB is an FDA-approved drug that has been used 
safely and without significant side effects for many years (Naylor et al., 1986).  
Studies of low dose MB in humans are needed to examine its effects in AD 
patients and those with MCI.   
5.6  Conclusions 
A major problem in AD research continues to be determining which 
abnormalities are primary and which are secondary.  Amyloid plaques, 
neurofibrillary tangles, oxidative stress, acetylcholine signaling, mtDNA 
mutations, decreased C.O. activity, brain hypometabolism, and neuronal 
degeneration are all interrelated.  In vitro, a defect in one can lead to 
abnormalities in the others.  Despite the difficulty in classifying the abnormalities, 
it is clear that C.O. inhibition is one of the first markers that appear in AD and in 
patients with MCI who develop AD.  Therapy aimed at improving C.O. activity 
might slow the decline of MCI to AD.  PCC hypometabolism is observed in 
patients with MCI who later develop AD and in subjects carrying a common AD 
susceptibility gene.  Measuring brain metabolism in the PCC could noninvasively 
evaluate the efficacy of drugs that target C.O.    
Sodium azide administration impairs C.O. activity and results in memory 
impairment in both aversively and appetitively-motivated tasks.  In rats, a primary 
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reduction in C.O. activity is sufficient to induce other pathological changes in the 
brain such as impaired LTP, decreased PKC activation, and a decrease in 
several markers of acetylcholine transmission (Bennett et al., 1992; Bennett et 
al., 1995; Luques et al., 2007).  Sodium azide-treated cells exhibit changes in 
amyloid processing (Gabuzda et al., 1994; Gasparini et al., 1997) and decreases 
in the mitochondrial membrane potential (Cassarino et al., 1998).  Rats treated 
with sodium azide reproduce several changes observed in AD patients.   
There is no animal model that can mimic all the cognitive, behavioral, 
biochemical and histopathological abnormalities observed in AD patients.  
However, an animal model of C.O. hypometabolism in the PCC can provide 
information to understand the mechanisms that regulate early pathological 
degeneration, provide information as to the underlying pathology, and possibly 
reveal new therapeutic strategies aimed at reducing or preventing cognitive 
decline.   
Hopefully, the proposed animal model of PCC hypometabolism can 
replicate some of the cognitive impairments and neuropathological changes that 
are observed in the earliest stages of AD.  Further investigation of this model 
may clarify pathological mechanisms and allow assessment of new treatment 
strategies.  MCI is now considered prodromal AD.  Therefore, it is crucial to try 
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